

# Index to Volume 36

The index to Volume 36 is composed of three parts: a subject index, an author index and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended controlled vocabulary index which makes use of standardized headings. (The primary index terms for each article are listed routinely in the *Journal* as "key words" following article abstracts.) The subject index also notes all regular *Journal* columns and, under the respective column headings, the titles of editorials and books reviewed, the items covered in "Equipment and Supplies," the titles of individual stories in "News" items, and reports from affiliated chapters in "ASHP Affiliates." Under "News," items covered in "Appointments and Promotions" and in "News Briefs" are listed after those subheadings. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page number on which the correction appeared.

Issue	Pages
January	1-130
February	131-270
March	271-418
April	419-570
May	571-714
June	715-862

Issue	Pages
July	863-1000
August	1001-1134
September	1135-1284
October	1285-1446
November	1447-1614
December	1615-1750

## Subject Index

### A

#### Absorption

aminophylline; oral, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059  
aspirin; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
diphylline; patients, 1179

#### Acetaminophen

combination, oxycodone; therapy, symptoms, folic acid allergies, patient, 1565  
hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
information; comparison, services, 1215

#### Additives

incompatibilities; glycopyrrolate, effects, pH, 508  
injections; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, in sodium chloride and dextrose in water, 657; cefoxitin sodium, stability, 33; diazepam, i.v., incompatibilities, plastics, 505; equipment, comparison, systems, contamination, costs and workload, 1497; FreAmine II, incompatibilities, 511; heparin sodium, stability, pH and time, in dextrose in water and dextrose in sodium chloride, 618; insulin, low-dose continuous, effects, availability, 330; intravenous, osmolality, methods, 1357; stability, glycopyrrolate, 508

#### Administration

clinical pharmacy; services, strategy, increased demand, hospitals, 1553  
hospital pharmacy; amino acids, parenteral nutrition solutions, concentration, formulary change, 57  
personnel, pharmacy; evaluations, methods, 187  
pharmacists, hospital; performance, appraisal, method, 1676  
policies and procedures; manuals, admixture services, parenteral nutrition, development, review, 517

#### Admixture services

injections; containers, plastics, dextrose in water, compounding times and contamination rates, 513; contamination during sterility testing, 1493; control, quality, methods and programs, 605

#### Admixtures

injections; containers, plastics, dextrose in water, compounding times and contamination rates, 513; contamination during sterility testing, 1493; control, quality, methods and programs, 605

#### Adsorption

insulin; injections, low-dose, continuous, effects, and solution type, container, administration set, concentration and rate, 330  
nitroglycerin; containers, plastics, extemporaneous i.v. injections, 173  
sodium salicylate; charcoal, activated, reduced by sucrose, in vitro, 797  
sucrose; charcoal, activated, lack, in vitro, 797

#### Adulteration

meperidine hydrochloride; dosage forms, visual, colorimetry and UV spectrometry, 1094

#### Advertising Index

128, 264, 446, 570, 714, 862, 1000, 1134, 1284, 1446, 1614, 1734

#### AJHP Continuing Education

11, 139, 279, 427, 581, 721, 869, 1011, 1145, 1291, 1453, 1623

#### Albumin

cardioplegic solutions; stability, effects, 1361  
drug use review; prescribing, hospitals, 1205

#### Allergies

allopurinol; patients, 1377  
folic acid; patient, 1565

#### Allopurinol

allergies; patients, 1377

gout; and hyperuricemia, therapy, discussion, 497  
sarcoidosis; therapy, discussion, 351

#### Aluminum hydroxide

combination, magnesium hydroxide; absorption, oral  
aminophylline, effects, patients, 1059  
combination, magnesium hydroxide, simethicone; tablets, equivalency, generic, acid reactivity, in vitro, 664

Ambulatory care; patients; pharmacists, role, clinic, screening and prescribing, 916

#### American Journal of Hospital Pharmacy

acknowledgment to reviewers, 1661  
notice to authors, 850, 1485  
statement of ownership, management and circulation, 1552

#### American Society of Hospital Pharmacists

accreditation standard for pharmacy residency in a hospital, 74

affiliated state chapter officers, 962

Board of Directors; actions, November 16-17, 1978 meeting, 224; March 22-23, 1979 meeting, 965; April 21, 1979 meeting, 966; July 30-31, 1979 meeting, 1559  
councils call for agenda suggestions, 964

Council on Clinical Pharmacy and Therapeutics; report of, 949

Council on Education and Manpower; report of, 950

Council on Legal and Public Affairs; report of, 952

Council on Organizational Affairs; report of, 954

Council on Professional Affairs; report of, 956

Donald E. Francke Medal lecture, 492

education; topics, 1967-1978, Midyear Clinical Meeting papers, 1372

Executive Vice President; report of, 944

Guidelines for obtaining authorization for pharmacists' notations in the patient medical record, 222

Guidelines for repackaging oral solids and liquids in single unit and unit dose packages, 223

Guidelines for the use of investigational drugs in institutions, 221

Harvey A. K. Whitney Lecture Award; 1978, 311

House of Delegates, 30th annual session; members of, 936; proceedings of, 934

Midyear Clinical Meeting, 1979; program, 1391

officers, directors, councils and committees; directory of, 957

President and Chairman of the Board; report of, 938

President-elect and Vice Chairman of the Board; report of, 941

Residents in training in accredited programs; calendar year 1978, 663

Statement of accreditation of pharmacy residencies in hospitals, 72

Treasurer; report of, 946

American Society of Hospital Pharmacists Residency Matching Program; residencies; hospitals, screening and selection procedure, 194

#### Amikacin

and ticarcillin; toxicity, ear, leukopenic patients, 1083  
drug use review; pharmacists, hospital, 1209

Amikacin sulfate; incompatibilities; cefoxitin sodium, lack, in vitro, 33

#### Amino acids

adverse reactions; rash, due to fatty acid deficiency, patient, 230  
concentration; parenteral nutrition, solutions, formulary change, hospitals, 57

#### Aminoglycosides

antibiotics; costs, pharmacists, hospital, role, 1209; toxicity, ear, leukopenic patients, 1083

blood levels; rational therapy, pharmacists, role, 1080  
dosage schedules; computers, costs, hospitals, 368  
infections; combined therapy, granulocytic cancer patients, 178

#### Aminophylline

absorption; oral, lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059  
dosage; oral, determination, using clearance rates following i.v. infusion, patients, 66  
tablets; comparison, theophylline sustained-action tablets, effects and blood levels, patients, 613

Amoxicillin trihydrate; stability; temperature, freezing, effects, reconstituted unit dose, 209

#### Amphotericin B

incompatibilities; FreAmine II, visual, 511  
mechanism of action; toxicity, dosage, availability and costs, review, 1326

#### Ampicillin

hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
stability; temperature, freezing, effects, reconstituted unit dose, 209

toxicity; diarrhea, prophylaxis, *Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*, patients, 754; skin, patients, 609

Ampicillin sodium; incompatibilities; FreAmine II, visual, 511

Ampule; stannous chloride dihydrate; ions stannous, effects, stability, radiopharmaceutical kits, 1370

#### Anaesthetics and antipyretics

butorphanol tartrate; therapy, review, 1683

costs; hospitals, and drug use, 1347

injections; self-medication, costs, effects, clinical pharmacists training programs, inpatient, 1527

meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094

phenothiazines; rational therapy, review, 633

therapy; review, 622

Analysis; microbiological; penicillin V potassium, stability, oral plastic syringes, various temperatures, 205

Anemia; Cooley's; deferoxamine, self-medication, patients, pharmacist, hospital, role, 788

#### Antacids

aluminum hydroxide, combination, magnesium hydroxide; lack, effects, oral aminophylline absorption, patients, 1059

aluminum hydroxide, combination, magnesium hydroxide, simethicone; tablets, equivalency, generic, and reactivity, in vitro, 660

interactions; tetracycline, monitoring, programs, outpatients, 653

#### Antibiotics

aminoglycosides; costs, pharmacists, hospital, role, 1209

drug use review; amikacin, and tobramycin, hospital pharmacists, 1209; cefazolin, prescribing, control, programs, hospital, 1055; hospitals, systems, problems, 376

incompatibilities; FreAmine II, 511

prescribing; effects, length of hospital stay, pyelonephritis patients, 1334

#### Anticoagulants

coumarin derivatives; drug interactions, monitoring, Medicaid patients, 923

heparin; dosage schedules, effects, costs, tests and errors, 920; injections, rates, methodology, comparison, patient weight and pharmacokinetic model, 782; solutions, use, cytopathology, bottles, collection of body cavity fluids,

## Index

211; thrombopenia, patients, 1561  
 heparin sodium and warfarin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
 pharmacists, hospital; role, clinic, ambulatory, development, operation, patient management protocols and education, 645  
 warfarin sodium; dosage, methodology, prothrombin time, patients, 1351  
 warfarin sodium and heparin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
**Anticonvulsants**; phenytoin; information, comparison, services, 1215  
**Antidiabetic agents**  
 patients; clinical pharmacists, role, management, 1321  
 tolbutamide; hyponatremia, patients, 1107; tablets, stability, storage, counting machine, spectrometry and colorimetry 1539  
**Antidiarrhea agents**  
*Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*; prophylaxis, ampicillin-induced diarrhea, patients, 754  
*Lactobacillus bulgaricus*, combination, *Lactobacillus acidophilus*; prophylaxis, ampicillin-induced diarrhea, patients, 754  
 therapy; review, 757  
**Antidotes**  
 atropine sulfate; injections, therapy, clonidine overdose, review, 906  
 charcoal activated; comparison, kaolin, combination, pectin, effects, aspirin absorption, patients, 1097; therapy, clonidine overdose, review, 906  
 cholestyramine resin; poisoning, digitoxin, patients, 92  
 colestipol hydrochloride; poisoning, digitoxin, patients, 92  
 dopamine; injections, therapy, clonidine overdose, review, 906  
 kaolin, combination, pectin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
 lidocaine hydrochloride; poisoning, digitoxin, patients, 92  
 pectin, combination, kaolin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
 phenytoin sodium; poisoning, digitoxin, patients, 92  
 poisoning; drugs, effects, electrolyte blood levels, patients, 1336  
 potassium chloride; poisoning, digitoxin, patients, 92  
 tolazoline; rational therapy, clonidine overdose, review, 906  
**Antihemophilic factor human**; self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527  
**Antihistamines**; chlorpheniramine maleate; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Anti-infective agents**; prescribing; effects, length of hospital stay, pyelonephritis patients, 1334  
**Anti-inflammatory agents**; therapy; review, 622  
**Antineoplastic agents**  
 cytarabine; self-medication, costs, effects, clinical pharmacists training programs, inpatients, 1527  
 doxorubicin hydrochloride; injections, stability, temperature, effects, 1536  
**Antiparkinson agents**; extrapyramidal disorders; prophylaxis, psychotherapeutic agent-induced, patients, 641  
**Antirheumatic agents**; therapy; review, 622  
**Arthritis**; therapy; review, 622  
**Ascorbic acid**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**ASHP, see American Society of Hospital Pharmacists**  
**ASHP Affiliates**, 17, 146, 284, 431, 587, 728, 872, 1016, 1148, 1297, 1458, 1630  
 Alabama Society of Hospital Pharmacists, 146, 284, 587, 1148, 1297  
 Arizona State Council of Hospital Pharmacists, 146, 1630  
 California Society of Hospital Pharmacists, 17, 146, 284, 431, 872, 1148  
 Colorado Society of Hospital Pharmacists, 1297  
 Connecticut Society of Hospital Pharmacists, 431, 587, 728, 1630  
 District of Columbia Society of Hospital Pharmacists, 1297  
 Florida Society of Hospital Pharmacists, 17, 284, 1016  
 Georgia Society of Hospital Pharmacists, 18, 587, 872, 1630  
 Idaho Society of Hospital Pharmacists, 18, 872  
 Indiana Society of Hospital Pharmacists, 1016  
 Iowa Society of Hospital Pharmacists, 431, 1458  
 Kansas Society of Hospital Pharmacists, 1297, 1639  
 Louisiana Society of Hospital Pharmacists, 1016, 1639  
 Maine Society of Hospital Pharmacists, 18, 431, 1646  
 Maryland Society of Hospital Pharmacists, 18, 284, 431, 728, 1021, 1148, 1646  
 Massachusetts Society of Hospital Pharmacists, 18, 286, 1021

Michigan Council of Hospital Pharmacists, 431  
 Minnesota Society of Hospital Pharmacists, 19, 590, 729  
 Missouri Society of Hospital Pharmacists, 19, 875, 1646  
 Montana Society of Hospital Pharmacists, 1458  
 Nebraska Society of Hospital Pharmacists, 19, 431, 875  
 New Jersey Society of Hospital Pharmacists, 146, 729, 878, 1297  
 New York State Council of Hospital Pharmacists, 19, 286, 878  
 North Carolina Society of Hospital Pharmacists, 432  
 Ohio Society of Hospital Pharmacists, 146  
 Oregon Society of Hospital Pharmacists, 432, 729, 1021  
 Pennsylvania Society of Hospital Pharmacists, 729, 1021, 1650  
 Rhode Island Society of Hospital Pharmacists, 732, 1150  
 Texas Society of Hospital Pharmacists, 732, 1458  
 Vermont Society of Hospital Pharmacists, 1297  
 Virginia Society of Hospital Pharmacists, 590, 1022, 1650  
 West Virginia Society of Hospital Pharmacists, 878  
 Wisconsin Society of Hospital Pharmacists, 878, 1458  
**Aspirin**  
 absorption; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
 hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
 interactions; phenothiazines, potentiation, review, 633  
 tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Asthma**; theophylline; tablets, sustained-action, dosage schedules, blood levels, children, 1698  
**Atropine**; diarrhea; therapy, discussion, 757  
**Atropine sulfate**; therapy; clonidine, overdose, review, 906  
**Audiovisual aids**; patients; education, theophylline, with and without pharmacists present, 63  
**Automation, data processing, computers**  
 adverse reactions; monitoring, programs, hospitalized patients, 198  
 aminoglycosides; dosage schedules, costs, 368  
 dosage schedules; pharmacokinetics, clinical pharmacists, development and reimbursement, 1523  
 drug use review; hypotensive agents, comparison, methods, family practice clinic, 1665  
 hospital pharmacy; comparison, word-processing machines, 1529; files, multi-functional drug, development, 1197; outpatients, services, 1978 survey, university-affiliated hospitals, 1193  
 pharmaceutical services; drugs, pricing, hospitals using a markup and a dose fee, 360  
**Azathioprine**; polychondritis, relapsing; therapy, patient, 806

## B

**Benzoic acid**; preservatives; effects, adulteration tests on mepheridine hydrochloride, 1094  
**Blood levels**  
 aminoglycosides; dosage schedules, computers, costs, 368; rational therapy, pharmacists, role, 1080  
 aminophylline; lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 digoxin; increased, quinidine, patient, 968  
 dyphylline; patients, 1179  
 gentamicin; ascitic patients, 1704  
 lidocaine hydrochloride; withdrawal, myocardial infarction patients, 778  
 naproxen; hemodialysis, effects, patients, 1567  
 spironolactone; effects, neomycin sulfate, patients 1701  
 theophylline; dosage, oral, using clearance rates following i.v. aminophylline infusion, patients, 66; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613; tablets, sustained-action, dosage schedules, asthmatic children, 1698  
**Book Reviews**, 109, 386, 531, 698, 823, 976, 1114, 1247, 1416, 1579, 1719  
*Annual Review of Pharmacology and Toxicology, Volume 19*, 1247  
*APhA Drug Names, Second Edition*, 823  
*Arterial Hypertension*, 531  
*Cancer Chemotherapeutic Agents: Handbook of Clinical Data*, 1719  
*Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists*, 823  
*Clinical Interviewing and Counseling: Principles and Techniques*, 1114

*Clinical Pharmacology of Anti-Neoplastic Drugs*, 698  
*Clinical Pharmacology of Psychotherapeutic Drugs*, 1416  
*Clinical Toxicology Manual*, 1417  
*Compliance in Health Care*, 1579  
*Containing Costs in Third Party Drug Programs: Selected Bibliography and Abstracts*, 824  
*Controlling the Smoking Epidemic*, 1581  
*Current Therapy 1979*, 1583  
*Dangerous Plants, Snakes, Arthropods & Marine Life: Toxicity and Treatment*, 976  
*Drug Assay: The Strategy of Therapeutic Drug Monitoring*, 1583  
*Drug Metabolism in Man*, 1721  
*Drug Toxicity*, 1417  
*The Evaluation of Continuing Education for Professionals: A Systems View*, 1420  
*Giving Medications Correctly and Safely*, 824  
*Guidelines for Parenteral Medication Usage*, 109  
*Handbook of Psychopharmacology, Volume 11, Stimulants*, 1420; *Volume 13, Biology of Mood and Anxiety Disorders*, 1421; *Volume 14, Affective Disorders: Drug Actions in Animals and Man*, 1584  
*Home Parenteral Nutrition: A Handbook*, 1586  
*Hospital Materiel Management*, 828  
*Hospital-associated Infections in the General Hospital Population and Specific Measures of Control*, 1588  
*Implementing Patient Education in the Hospital*, 1114  
*Improving Management Performance in Health Care Institutions: A Total Systems Approach*, 1247  
*Interpretation of Diagnostic Tests: A Handbook Synopsis of Laboratory Medicine, Third Edition*, 1588  
*Interviewing: A Guide for Health Professionals, Second Edition*, 828  
*An Introduction to Human Pharmacology*, 1588  
*Issues in Pharmaceutical Economics*, 1588  
*Manual of Dermatologic Therapeutics with Essentials of Diagnosis, 2nd Edition*, 386  
*Manual of Neurologic Therapeutics with Essentials of Diagnosis*, 109  
*Media Handbook: A Guide to Selecting, Producing, and Using Media for Patient Education Programs*, 979  
*Medication Teaching Manual: A Guide for Patient Counseling*, 532  
*New Trends and Developments in Vaccines*, 542  
*Nutrition and Drug Interrelations*, 391  
*Pharmacy in Health Care and Institutional Systems*, 546  
*Pharmacy Technician Training Manual, Third Edition*, 1421  
*Principles of Drug Information Services: A Syllabus of Systematic Concepts*, 834  
*Psychiatric Drugs: A Desk Reference: Second Edition*, 546  
*Review of Medical Pharmacology, Sixth Edition*, 110  
*Side Effects of Drugs, Annual 3*, 1116  
*Sourcebook on Computers in Pharmacy*, 838  
*Staff Manual for Teaching Patients about Chronic Obstructive Lung Diseases*, 1117  
*Staff Manual for Teaching Patients about Diabetes Mellitus*, 1117  
*Staff Manual for Teaching Patients about Hypertension*, 1118  
*Staff Manual for Teaching Patients about Rheumatoid Arthritis*, 1118  
*Sterile Dosage Forms. Their Preparation and Clinical Application*, 1253  
*Successful Personnel Recruiting and Selection within EEO/Affirmative Action Guidelines*, 1594  
*Surveillance for the Prevention and Control of Health Hazards Due to Antibiotic-resistant Enterobacteria*, 550  
*Textbook of Biopharmaceutics and Clinical Pharmacokinetics*, 1422  
*Treatment of Epilepsy Today*, 550  
**Books Received**, 110, 250, 391, 550, 702, 838, 980, 1118, 1258, 1428, 1598, 1722  
**Bretium tosylate**; pharmacokinetics; adverse reactions, dosage, interactions, review, 1189  
**Bronchodilators**; theophylline; dosage, oral, aminophylline, using clearance rates following i.v. infusion, patients, 66  
**Buffers**; cardioplegic solutions; stability, effects, 1361  
**Butorphanol tartrate**; therapy; toxicity, pharmacokinetics, dosage, review, 1683

## C

**Calcitonin**; self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527  
**Canrenone**; metabolites; spironolactone, blood levels, following neomycin sulfate, patients, 1701  
**Capsules**; phenytoin sodium; stability, storage, counting

machine, spectrometry and colorimetry, 1539

**Carbenicillin**; infections; combined therapy, granulocytic cancer patients, 178

**Cardiac drugs**

bretium tosylate; pharmacokinetics, adverse reactions, dosage, interactions, review, 1189

digitalis; drug interactions, monitoring, Medicaid patients, 923; interactions, outpatients, monitoring, programs, 653

digoxin; poisoning, antidotes, patients, 92

digoxin; interactions, quinidine, increased digoxin blood levels, patient, 968

lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmias, myocardial infarction patients, 778

pentamethylol tetranitrate; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

propafenone hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

quinidine sulfate; interactions, digoxin, increased blood levels, patients, 968

**Cardioplegic solutions**; formulations; manufacturing, and quality control, hospital pharmacy, 1361

**Carts**; pharmaceutical services; decentralized, without satellites, 1513

**Catheters**; plastics; toxicity, thrombosis, patients, effects, physical characteristics, 1707

**Cefamandole nafate**; pharmacokinetics; adverse reactions, dosage, effects, review, 1503

**Cefazolin**; prescriptions; prescribing, control, programs, hospital, 1055

**Cefazolin sodium**

infections; combined therapy, granulocytic cancer patients, 178

injections; filters, membrane, effects, concentration and particulate contamination, in sodium chloride and dextrose in water, 657

**Cefoxitin sodium**

incompatibilities; lack, amikacin sulfate, gentamicin sulfate, kanamycin sulfate, tobramycin sulfate and lidocaine hydrochloride, in vitro, 33

pharmacokinetics; adverse reactions, dosage, effects, review, 1503

**Cephalosporins**; costs; hospitals, and drug use, 1347

**Cephalothin**

costs; hospitals and drug use, 1347

toxicity; skin, patients, 609

**Cephalothin sodium**; infections; combined therapy, granulocytic cancer patients, 178

**Charcoal activated**

adsorption; sucrose, lack, in vitro, 797

comparison, kaolin, combination, pectin; effects, aspirin absorption, patients, 1097

therapy; clonidine, overdose, review, 906

**Charges**; pharmaceutical services; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, based upon medication administration record, 365; hospitals, based upon per-diem drug costs, 363; hospitals, computerized system using markup and a dose fee, 360

**Chloramphenicol sodium succinate**; incompatibilities; glycopyrrolate, effects, pH, 508

**Chloroquine**; narcosis; therapy, discussion, 351

**Chlorothiazide**; adverse reactions; hyponatremia, patients, 1107

**Chlorpheniramine maleate**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Cholestyramine resin**

antidotes; poisoning, digitoxin, patients, 92

diarrhea; therapy, discussion, 757

**Cisplatin**; stability; solutions, UV spectrometry, 38

**Classified Advertising**, 120, 256, 403, 561, 704, 847, 985, 1125, 1266, 1431, 1604, 1725

**Clinical Forum**, 89, 230, 674, 806, 968, 1103, 1377, 1561

**Clinical pharmacists**

consultation; patients, family practice office, 912

dosage schedules; pharmacokinetics, development and reimbursement, 1523

role; patients, diabetes mellitus and hypertension, management, 1321

rounds; toxicity, skin, monitoring, hospitals, patients, 609

self-medication; role, cost savings, inpatients, 1527

workload; drug use review, hypotensive agents, family practice clinic, 1665

**Clinical pharmacy**

aminoglycosides; blood levels, rational therapy, pharmacists, role, 1080

anticoagulants; services, ambulatory clinic, 645

consultation; poisoning, pediatrics, clinical toxicology service, 1087

decentralized; emergency room, costs, 52

effects; drug information, services, hospitals, 1520

Harvey A. K. Whitney Lecture Award; 1978, 311

outpatients; services, survey, 1978, university-affiliated hospitals, 1193

parenteral nutrition; therapy, effects, patient outcome and costs, 785

patient information; consultation, deferaxamine, Cooley's anemia patients, 788

patients; ambulatory, clinic, screening and prescribing, 916

reimbursement; third-party, pharmacokinetic dosage schedules, 1521

services; charges, hospitals, based upon drug cost plus per-diem fees, 355; effects, adverse reactions, length of stay, inpatients, 1691; effects, patients' perceptions of health care quality, 325; hospitals, strategy, increased demand, 1553; hospitals, survey, 1978, 316; reimbursement, third-party, models, 1548

**Clonidine**

dosage; overdose, and therapy, review, 906

dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802

**Clotrimazole**; mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Codeine**; diarrhea; therapy, discussion, 757

**Colchicine**; gout; and hyperuricemia, therapy, discussion, 497

**Colistipol hydrochloride**; antidotes; poisoning, digitoxin, patients, 92

**Colorimetry**

dosage forms; tablets, and capsules, storage, counting machine, effects on stability, 1539

meperidine hydrochloride; dosage forms, adulteration, 1094

**Combined therapy**

amikacin and ticarcillin; toxicity, ear, leukopenic patients, 1083

gentamicin and ticarcillin; toxicity, ear, leukopenic patients, 1083

netilmicin and ticarcillin; toxicity, ear, leukopenic patients, 1083

ticarcillin and amikacin, gentamicin or netilmicin; toxicity, ear, leukopenic patients, 1083

**Concentration**

amino acids; parenteral nutrition, solutions, formulary change, hospitals, 57

cefazolin sodium; injections, effects, membrane filters, in sodium chloride and dextrose in water, 657

insulin; availability, effects, low-dose continuous injections, 330

**Containers**

cefazolin sodium; effects, on stability, additives, 33

heparin; solutions, use, collection of body cavity fluids, 211

insulin; injections, continuous low-dose, effects, glass and polyvinyl chloride, 330

nitroglycerin; plastics, and glass, extemporaneous, i.v. injections, stability, 173

plastics; admixtures, injections, dextrose in water, compounding times and contamination rates, 513; incompatibilities, diazepam, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

**Contamination**

admixtures; injections, during sterility testing, 1493; injections, plastic containers, dextrose in water, 513

injections; i.v., comparison, systems, 1497; i.v., effects of membrane final filter pore size on survival, rabbits, 1711; i.v., plethysm, effects, inline membrane final filters, postoperative patients, 1355

microbiological; injections, and administration sets, determination, membrane filter set, 1202; solutions, protein hydrolysates and dextrose, prevention, sodium acetate, 1672

particles; cefazolin sodium, injections, in sodium chloride and dextrose in water, 657

**Contraceptives, oral**

mestranol, combination, norethindrone; ischemic bowel disease, patient, 1103

norethindrone, combination, mestranol; ischemic bowel disease, patient, 1103

**Control**

inventory; hospital pharmacy, computerized system, 360

prescribing; cefazolin, programs, hospital, 1055

purchasing; drugs, and inventory, hospitals, U.S., General Accounting Office report, 1171

**Control, quality**; cardioplegic solutions; manufacturing, hospital pharmacy, 1361

**Control, quality see also Quality assurance**

**Correction Notices**, 305, 600, 745, 1050, 1166, 1660

Bretium tosylate: A review (Sep 1979), 1660

Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acid solution (Jan 1978), 600

Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives (Apr 1979), 745

Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures (Oct 1978), 305

Proceedings of the 30th Annual Session of the ASHP House of Delegates (Jul 1979), 1166

Roster of residents in training programs accredited by the American Society of Hospital Pharmacists—calendar year 1978 (May 1979), 1050

**Costs**

albumin; prescribing, drug use review, hospitals, 1205

amikacin; pharmacists, hospital, monitoring, 1209

antibiotics; rational therapy, hospitalized pyelonephritis patients, 1334

anti-infective agents; rational therapy, hospitalized pyelonephritis patients, 1334

computers; hospital pharmacy, development of multifunctional drug file, 1197

drug information; systems, evaluation, 793

drug use review; hypotensive agents, comparison, methods, family practice clinic, 1665

drugs; effects, decentralized operating room pharmacy services, 1342; records, use in developing drug use profiles, hospitals, 1347

education; patients, adrenalectomy, hospital pharmacists, 1212

fungicides; discussion, 1326

heparin; effects, dosage schedules, based upon pharmacokinetics, 920

injections; i.v., comparison, systems, 1497

parenteral nutrition; decreased, formulary change in amino acid concentration, 57; therapy, pharmacists, role, 785

pharmaceutical services; decentralized, without satellites, 1513; hospitals, based upon drug cost plus per-diem fees, 355

pharmacokinetics; services, hospitals, 368

pharmacy; services, decentralized, emergency room, 52

reprints; journals, articles, 1219

self-medication; inpatients, decreased, clinical pharmacists, role, 1527

tobramycin; pharmacists, hospital, monitoring, 1209

**Coumarin derivatives**; drug interactions; monitoring, Medicaid patients, 923

**m-Cresol**; preservatives; effects, adulteration tests on meperidine hydrochloride, 1094

**Current Literature**, 96, 241, 381, 522, 686, 817, 972, 1112, 1237, 1410, 1570, 1714

**Cytarabine**; self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527

## D

**Deferoxamine**; patient information; pharmacists, hospital, consultation, Cooley's anemia patients, 788

**de Haen Drugs in Use**; drug information; comparison, other services, 1215

**Deserpidine**; drug interactions; monitoring, Medicaid patients, 923

**Dexamethasone**; self-medication; patients, adrenalectomy, education, by hospital pharmacists, 1212

**Dexamethasone sodium phosphate**; incompatibilities, glycopyrrolate, effects, pH, 508

**Dextran 70**; adverse reactions; mechanism of action, thrombotic thrombocytopenic purpura patient, 89

**Dextrose**

additives; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, 657; injections, diazepam, i.v., incompatibilities, plastics, 505

admixtures; injections, plastic containers, compounding times and contamination rates, 513

adulteration; meperidine hydrochloride, dosage forms, 1094

alone and with sodium chloride; solutions, effects, insulin availability, low-dose continuous injections, 330

diluent; effects, stability, extemporaneous nitroglycerin i.v. injections, 173

and FreAmine II; additives, stability, incompatibilities, 511

heparin sodium; stability, 618

injections; contamination, microbiological, determination, membrane filter set, 1202

parenteral nutrition; adverse reactions, due to fat-free content, patient, 230

solutions; osmolality, methods, 1357; sodium acetate, preservatives, 1672

**Dialysis**; hemo; effects, naproxen blood levels, patients, 1567

**Diazepam**

costs; hospitals and drug use, 1347

incompatibilities; glycopyrrolate, effects, pH, 508; plastics, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Digitalis**

drug interactions; monitoring, Medicaid patients, 923

interactions; diuretics, monitoring, programs, outpatients, 653

**Digitoxin**; poisoning; antidotes, patients, 92

**Digoxin**; interactions; hydrochlorothiazide, monitoring, programs, outpatients, 653

quinidine, increased digoxin blood levels, patient, 968

**Diluents**

dextrose; effects, stability, extemporaneous nitroglycerin



## Index

i.v. injections, 173  
 sodium chloride; effects, stability, extemporaneous nitroglycerin i.v. injections, 173  
**Dimenhydrinate**; incompatibilities; glycopyrrolate, effects, pH, 508  
**Diphenoxylate**; diarrhea; therapy, discussion, 757  
**Dipyridamole**; purpura; thrombotic thrombocytopenic, therapy, patient, 89  
**Disaster planning**; hospital pharmacy; personnel, role, 1337  
**Disintegration**; dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539  
**Dissolution**; dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539  
**Diuretics**  
 chlorothiazide; hyponatremia, patients, 1107  
 furosemide; dosage schedules, comparison, once and twice daily, excretion, patients, 68  
 interactions; digitalis, monitoring, programs, outpatients, 653  
 Reye's syndrome; therapy, review, 767  
 spironolactone; availability, effects, neomycin sulfate, patients, 1701; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Dopamine**; injections; therapy, clonidine overdose, review, 906  
**Dosage**  
 albumin; rational therapy, hospitals, 1205  
 amphotericin B; review, 1326  
 anticoagulants; monitoring, pharmacists, hospital, 214  
 bretylium tosylate; review, 1189  
 butorphanol tartrate; review, 1683  
 cefamandole nafate; review, 1503  
 cefoxitin sodium; review, 1503  
 clonidine; overdose, and therapy, review, 906  
 clotrimazole; review, 1326  
 flucytosine; review, 1326  
 gentamicin; relation, blood levels, ascitic patients, 1704  
 griseofulvin; review, 1326  
 insulin; low, injections, continuous availability, effects of solution type, container, administration set, concentration and rate, 330  
 methenamine hippurate; review, 1509  
 methenamine mandelate; review, 1509  
 miconazole nitrate; review, 1326  
 nalidixic acid; review, 1071  
 nystatin; review, 1326  
 oxolinic acid; review, 1077  
 steroids; cortico-; education, adrenalectomy, patients, by hospital pharmacists, 1212  
 theophylline; oral, using clearance rates following i.v. infusion, patients, 66  
 warfarin sodium; methodology, prothrombin time, patients, 1351  
**Dosage forms**  
 aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 meperidine hydrochloride; adulteration, visual, colorimetry and UV spectrometry, 1094  
 theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613  
**Dosage schedules**  
 amikacin; pharmacists, hospital, role, 1209  
 aminoglycosides; computers, costs, hospitals, 368  
 aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 furosemide; comparison, once and twice daily, excretion, patients, 68  
 heparin; pharmacokinetics, effects, costs, tests and errors, 920  
 hypotensive agents; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802; pharmacokinetics, discussion, 1222  
 lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmias, myocardial infarction patients, 778  
 pharmacokinetics; clinical pharmacists, development and reimbursement, 1523  
 theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613; tablets, sustained-action, blood levels, asthmatic children, 1698  
 tobramycin; pharmacists, hospital, role, 1209  
**Doxorubicin hydrochloride**; injections; stability, effects, temperature, 1536  
**Drug administration**  
 education, pharmaceutical; internships, students, 791  
 hospitals; effects, adverse reactions, length of stay, inpatients, 1691  
 injections; flow, rates, models, 338; i.v., flow rates, clamps, comparison, electronic controller, 1090  
 self-medication; clinical pharmacists, role, cost savings, inpatients, 1527; deferaxamine, Cooley's anemia patients, role of hospital pharmacist, 788; dexamethasone, adrenalectomy patients, role, hospital pharmacists, 1212  
**Drug distribution systems**  
 hospitals; effects, adverse reactions, length of stay, in-

patients, 1691  
 unit dose; carts, decentralized pharmaceutical service without satellites, 1513; hospitals, survey, 1978, comparison, 1975, 316  
**Drug information**  
 admixture services; injections, manuals, development, review, 517  
 anticoagulants; pharmacists, hospital, bulletin, 214  
 parenteral nutrition; manuals, development, review, 517  
 services; clinical pharmacy, effects, hospitals, 1520; comparison, 1215  
 systems; evaluations, method, 793  
**Drug interactions**  
 aluminum hydroxide, combination, magnesium hydroxide and aminophylline; lack, effects, absorption, patients, 1059  
 aminoglycosides and cephalothin sodium; toxicity, kidney, granulocytic cancer patients, 178  
 aminophylline and aluminum hydroxide, combination, magnesium hydroxide; lack, effects, absorption, patients, 1059  
 antacids and tetracycline; monitoring, programs, outpatients, 653  
 aspirin and phenothiazines; potentiation, review, 633  
 bretylium tosylate; review, 1189  
 cephalothin sodium and aminoglycosides; toxicity, kidney, granulocytic cancer patients, 178  
 digitalis and diuretics; monitoring, programs, outpatients, 653  
 digoxin and hydrochlorothiazide; monitoring, programs, outpatients, 653  
 digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968  
 diuretics and digitalis; monitoring, programs, outpatients, 653  
 drugs, nonprescription; monitoring, programs, outpatients, 653  
 hydrochlorothiazide and digoxin; monitoring, programs, outpatients, 653  
 information; systems, evaluation, 793  
 meperidine and phenothiazines; potentiation, review, 633  
 monitoring; patients, Medicaid, 923; programs, ambulatory outpatients, based upon medical-record review, patient interviews and laboratory-test evaluations, 653  
 morphine sulfate and phenothiazines; potentiation, review, 633  
 nalidixic acid; review, 1071  
 neomycin sulfate and spironolactone; effects, spironolactone availability, patients, 1701  
 phenothiazines and aspirin, meperidine and morphine sulfate; potentiation, review, 633  
 quinidine sulfate and digoxin; blood levels, digoxin, increased, patient, 968  
 spironolactone and neomycin sulfate; effects, spironolactone availability, patients, 1701  
 sulfamethoxazole, combination, trimethoprim; review, 893  
 trimethoprim, combination, sulfamethoxazole; review, 893  
**Drug Reaction Alerts**, 96, 243, 383, 522, 694, 821, 975, 1112, 1237, 1413, 1573, 1716  
**Drug Regulation Reform Act of 1979**; laws; provisions, Kennedy bill, 1230  
**Drug Therapy Reviews**, 342, 351, 497, 622, 757, 893, 1071, 1077, 1185, 1326, 1503, 1683  
**Drug use**; toxicity; skin, patients, hospitals, 609  
**Drug use review**  
 amikacin; pharmacists, hospital, 1209  
 antibiotics; hospitals, systems, problems, 376; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
 anti-infective agents; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
 cefazolin; prescribing, control, programs, hospital, 1055  
 effects; rational therapy, discussion, 1099  
 heparin sodium and warfarin sodium; pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
 hospital pharmacy; computers, use, 1197  
 hospitals; effects, drug-charge records, 1347  
 hypotensive agents; comparison, methods, family-practice clinic, 1665  
 interactions; monitoring, Medicaid patients, 923  
 pharmacist involvement; hospitals, survey, 1978, comparison, 1975, 316  
 tobramycin; pharmacists, hospital, 1209  
 warfarin sodium and heparin sodium; pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
**Drug utilization review**, see **Drug use review**  
**Drug withdrawal**; lidocaine hydrochloride; lack, ventricular arrhythmias, myocardial infarction patients, 778  
**Drugs**  
 selection; erythromycin, and derivatives, review, 1185

therapy; methodology, systematic problem-solving approach, 798  
**Drugs, adverse reactions**  
 allopurinol; allergies, patients, 1377  
 amikacin; monitoring, pharmacists, hospital, 1209  
 amino acids; rash, due to fatty-acid deficiency, patient, 230  
 bretylium tosylate; review, 1189  
 cefamandole nafate; review, 1503  
 cefoxitin sodium; review, 1503  
 chlorothiazide; hyponatremia, patients, 1107  
 dextran 70; mechanism of action, thrombotic thrombocytopenic purpura patient, 89  
 dextrose; solutions, due to fat-free content, patient, 230  
 erythromycin; and derivatives, review, 1185  
 folic acid; allergies, patient, 1565  
 heparin; thrombopenia, patients, 1561  
 hospitals; effects, drug distribution systems, drug administration systems, drug administration and clinical pharmacy services, inpatients, 1691  
 iatrogenic diseases; skin, monitoring, hospitals, patients, 609  
 lidocaine hydrochloride; lack, ventricular arrhythmia, upon withdrawal, myocardial infarction patients, 778  
 meperidine, combination, norethindrone; ischemic bowel disease, patient, 1103  
 methenamine hippurate; review, 1509  
 methenamine mandelate; review, 1509  
 monitoring; computers, programs, hospitalized patients, 198  
 nalidixic acid; review, 1071  
 norethindrone, combination, meperidine; ischemic bowel disease, patient, 1103  
 oxolinic acid; review, 1077  
 parenteral nutrition; solutions, fat-free, patient, 230  
 phenothiazines; review, 633  
 pneumococcal vaccines; review, 773  
 sulfamethoxazole, combination, trimethoprim; review, 893  
 thioridazine; hyperpyrexia, schizophrenic patient, 674  
 tobramycin; monitoring, pharmacists, hospital, 1209  
 tolbutamide; hyponatremia, patients, 1107  
 trimethoprim, combination, sulfamethoxazole; review, 893  
**Drugs, availability**  
 aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 amphotericin B; review, 1326  
 aspirin; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
 clotrimazole; review, 1326  
 flucytosine; review, 1326  
 griseofulvin; review, 1326  
 information; services, comparison, 1215  
 insulin; injections, low-dose, continuous, effects of solution type, container, administration set, concentration and rate, 330  
 miconazole nitrate; review, 1326  
 nystatin; review, 1326  
 spironolactone; effects, neomycin sulfate, patients, 1701  
 theophylline; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613  
**Drugs, body distribution**  
 gentamicin; ascitic patients, 1704  
 naproxen; effects, hemodialysis, patients, 1567  
**Drugs, clinical effectiveness**  
 aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613  
**Drugs, nonprescription**; interactions; monitoring, programs, outpatients, 653  
**Dyphylline**; pharmacokinetics; patients, 1179

## E

**Economics**; hospital pharmacy; purchasing, and inventory, statistics, 1978 survey, 650  
**Editorials**, 31, 169, 170, 307, 308, 455, 603, 747, 891, 1053, 1169, 1319, 1489, 1490, 1663  
 Administrative direction for clinical practice, 308  
 The ASHP SIGs: Sound beginning, promising future, 1169  
 Contamination: Lost or found? 1489  
 The decline and fall of secundum arterium, 1053  
 Economics of hospital pharmacy practice, i: Third-party reimbursement, 169; ii: Charging for services, 307  
 Expiration dates of repackaged drug products, 170  
 Hospital cost containment and the pharmacist, 31  
 On the road to assuring competence, 747  
 Pharmaceutical marketing: New rules for an old game, 603  
 Rationing hospital services, 1319  
 Reviewing the 1970s: The American Society of Hospital Pharmacists, 1663

Reviewing the 1970s: Hospital pharmacy practice, 1490

Underpriced ASHP membership dues: Long-range folly?, 891

The written word, 455

## Education

anticoagulants; patients, ambulatory, clinic, pharmacists, hospital, role, 645

nurses; continuing, one-day program, by pharmacists, 44

outpatients; survey, 1978, university-affiliated hospitals, 1193

patients; adrenalectomy, by hospital pharmacists, 1212; warfarin, hospitals, pharmacists and nurses, 219; theophylline, audiovisual, with and without pharmacists present, 63

personnel; admixtures, injections, control, quality, 605 physicians; antibiotics, aminoglycosides, by hospital pharmacists, 1209

## Education, pharmaceutical

American Society of Hospital Pharmacists; topics, 1967-1978, Midyear Clinical Meeting papers, 1372

continuing; hospital pharmacy, decentralized, staff program, 50

internships; students, emphasis on nursing assistant and medication administration through nursing service, 791

residencies; hospitals, screening and selection procedure, 194

technicians; programs, training, 1533

Electrolytes; solutions; osmolality, methods, 1357

Emetics; ipecac; effects, electrolyte blood levels, comparison, lavage patients, 1366

## Equipment

administration sets; electronic, comparison, clamps, i.v. flow rates, 1090; models, flow rates, 338

clamps; flow rates, i.v. injections, comparison, electronic controller, 1090

counting machines; storage, tablets, and capsules, effects on stability, 1539

hospital pharmacy; word-processing machines, compared, 1529

injections; i.v., comparison, systems, contamination, costs and workload, 1497

Equipment and Supplies, 114, 555, 1119, 1599

Abbott Laboratories, infusion pumps, 115; pump sets, 1122

American Optical Corporation, refractometer, 1123

Apex Medical Supply, Inc., educational materials, 1124; medicine dropper, 116

Barnstead Company, NANOpure system, 116

Baxa Corporation, bottle adapter, 115; oral liquid dispenser, 555

Burleson Airology Corporation, laminar-flow workstation, 1119

Burron Medical Products, administration sets, 115; double-filtered i.v. set, 559; filter needle, 1122; primary additive i.v. set, 1122

Cormed, Inc., mobile infusion pumps, 1599

Corning Glass Works, pH meter, 558

Cosa Corporation, deionizer, 1599

Drustar, Inc., drug-control systems, 1600; punch-card system, 1124

Dycem Limited, contamination-control mats, 1122

General Computer Corporation, hardware/software package, 116

Greene Pharmaceutical Instruments B.V., suppository machine, 1603

Healthmark Industries Co., autoclavable plastic bags, 114; autoclavable plastic trays, 1603; sterilizing tray, 1123; tote boxes, 560

Hierath & Andrews Corp., weighing system, 1119

IMED Corporation, equipment pole, 558; volumetric infusion pump, 116

IVAC Corporation, volumetric infusion pump, 1123

Jobar Corporation, catalog, 560

Kaymont Consolidated Industries, Inc., humidity-measuring instrument, 116

Lerner Packaging, brochure, 1124

Marvel Division, Dayton-Walther Corporation, refrigerator, 1599

McGaw Laboratories, PDI system, 559

Medi-Dose, Inc., lid-labels, 559

Herman Miller, Inc., Co/Struc System, 1116

Millipore Corporation, Addi-Chek system, 115; disposable filter unit, 1600

Modern Controls, Inc., blister-pack leak tester, 1600; bottle-leak tester, 1122

New England Applied Research, radiopharmaceutical analyzer, 1600

NCR Corporation, software package, 114

Pall Trinity Micor Corporation, brochure, 560

Parke, Davis & Company, laminar flow hood, 1599; medication cart, 1119; medication-control module, 555; night cabinet, 114

Penco Products, Inc., laboratory shelving, 115

Polyfoam Packers Corporation, catalog, 1124; containers, 555

RC Smith Company, modular furniture, 1122

RX Tool Company, cap remover, 558

Sigmamotor, Inc., infusion pump, 1122

Spacesaver Corporation, brochure, 560

Storex Corporation, catalog, 560

Telcoa International Corporation, security system, 555

Testing Machines Inc., testing devices, 1600

United Utensils, Co., Inc., bracket, 555

Wave Energy Systems, Inc., brochure, 560

Wheaton Instruments, dispenser, 115; Unispense, 560

Whitman Medical Corporation, i.v. stabilizer, 1600

## Equivalency

aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613

theophylline; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613

## Equivalency, generic

aluminum hydroxide, combination, magnesium hydroxide, simethicone; tablets, acid reactivity, in vitro, 660

magnesium hydroxide, combination, aluminum hydroxide, simethicone; tablets, acid reactivity, in vitro, 660

simethicone, combination, aluminum hydroxide, magnesium hydroxide; tablets, acid reactivity, in vitro, 660

Errors, medication

albumin; prescribing, hospitals, 1205

heparin; effects, dosage schedules, based upon pharmacokinetics, 920

injections; i.v. flow rates, clamps, comparison, electronic controller, 1090

omission; compliance, heparin sodium and warfarin sodium, monitoring, hospital pharmacists, 214; compliance, patients, diabetes mellitus and hypertension, clinical pharmacists, role, management, 1321

Erythromycin; and derivatives; mechanism of action, pharmacokinetics, adverse reactions, rational therapy, review, 1185

Estrogens; rational therapy; patients, peri- and postmenopausal, review, 1062

Excretion

aspirin; urinary, effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097

dyphylline; patients, 1179

furosemide; dosage schedules, determination, once and twice daily, patients, 68

lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmia, myocardial infarction patients, 778

spironolactone; urinary, effects, neomycin sulfate, patients, 1701

theophylline; dosage, oral, using clearance rates following i.v. aminophylline infusion, patients, 66

Extrapyramidal disorders; antiparkinson agents; prophylaxis, psychotherapeutic agent-induced, patients, 641

## F

Filters; membrane; air-venting, effects, air flow, administration sets, 749; contamination, microbiological, determination, injections and administration sets, 1202; inline, final, pore size, effects, survival following infusion of contaminated i.v. fluids, rabbits, 1711; inline, therapy, effects, phlebitis, postoperative patients, 1355

Flavors; sucrose; adsorption, charcoal activated, lack, in vitro, 797

Flow; rates; administration sets, models, 338; injections, i.v., clamps, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

Flucytosine; mechanism of action; toxicity, dosage, availability and costs, review, 1326

Folic acid; allergies; patients, 1565

Food and Drug Administration (U.S.); regulations; package inserts, patients, pharmacist's responsibility, 226

Forms

drugs; costs, use in developing drug-use profiles, hospitals, 1347

prescriptions; pharmacists, role, prescribing, ambulatory clinic patients, 916

records; medical, hospitals, determination, drug charges, 365

reprints; journals, articles, 1219

Formularies

amino acids; concentration, parenteral nutrition, solutions, changes, hospitals, 57

effects; rational therapy, discussion, 1099

hospital pharmacy; computers, use, 1197

hospitals; effects, decentralized pharmacy services, operating room and recovery room, 1342

Formulations

aluminum hydroxide, combination, magnesium hydroxide, simethicone; tablets, effects, acid reactivity, in vitro, 660

cardioplegic solutions, manufacturing, and quality control, hospital pharmacy, 1361

nitroglycerin; injections, i.v., extemporaneous, stability,

173

stannous chloride dihydrate; ions, stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370

Fracke, Donald E.; biographical information, 486; remarks at the memorial service, 459; remembrances: family, friends, students and colleagues, 462

FreAmine II; incompatibilities; additives, discoloration and precipitation, 508

FreAmine II, see also Amino acids

Furosemide; dosage schedules; comparison, once and twice daily, excretion, patients, 68

## G

### Gentamicin

and ticarcillin; toxicity, ear, leukopenic patients, 1083 pharmacokinetics; ascitic patients, 1704

Gentamicin sulfate

incompatibilities; cefoxitin sodium, lack, in vitro, 33

infections; combined therapy, granulocytic cancer patients, 178

Glass; containers; diazepam, injections, i.v., decreased stability, 505; effects, insulin, availability, low-dose, continuous injections, 330; effects, stability, extemporaneous nitroglycerin i.v. injections, 173

Glycerin; Reye's syndrome; therapy, review, 767

Glycopyrrolate; incompatibilities; additives, effects, pH, 508

### Gout

allopurinol; and hyperuricemia, therapy, discussion, 497

colchicine; and hyperuricemia, therapy, discussion, 497

indomethacin; and hyperuricemia, therapy, discussion, 497

oxyphenbutazone; and hyperuricemia, therapy, discussion, 497

phenylbutazone; and hyperuricemia, therapy, discussion, 497

probenecid; and hyperuricemia, therapy, discussion, 497

sulfapyrazone; and hyperuricemia, therapy, discussion, 497

Great Britain; history; pharmacists, hospital, 492

Griseofulvin; toxicity, dosage; availability and costs, review, 1326

Guanethidine; drug interactions; monitoring, Medicaid patients, 923

## H

### Half-life

dyphylline; patients, 1179

gentamicin; ascitic patients, 1704

spironolactone; effects, neomycin sulfate, patients, 1701

Harvey A. K. Whitney Lecture Award; American Society of Hospital Pharmacists; 1978, 311

Health benefit programs; third-party; costs, savings, inpatients, self-medication programs, 1527; Medicaid, monitoring, drug interactions, patients, 923; reimbursement, clinical pharmaceutical services, models, 1548

Health care; patients; ambulatory, clinic, pharmacists, role, screening and prescribing, 916; effects, clinical pharmacist consultation, family-practice office, 912; quality, effects, clinical pharmaceutical services, 325

Heparin

adverse reactions; thrombopenia, patients, 1561

dosage schedules; pharmacokinetics, effects, costs, tests and errors, 920

injections; rates, methodology, comparison, pharmacokinetic model and patient weight, 782

solutions; use, cytopathology, bottles, collection of body cavity fluids, 111

Heparin sodium

vehicles; stability, pH and time, in dextrose in water and dextrose in sodium chloride, 618

and warfarin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214

History; Great Britain; pharmacists, hospital, 492

Homatropine hydrobromide; solutions, ophthalmic; polycondritis, relapsing, therapy, patient, 806

Hospital pharmacy, see Pharmacy, institutional, hospital

Hospitals

adverse reactions; computers, monitoring, programs, 198

clinical pharmacy; services, strategy, increased demand, 1553

costs; antibiotics, aminoglycosides, pharmacists, role, 1209

drug use review; albumin, prescribing, 1205; antibiotics, systems, problems, 376

drugs; charges based upon medication administration record, 365; costs, use in developing drug-use profiles, 1347; purchasing, and inventory, U.S., General Accounting Office report, 1171

drugs, adverse reactions; length of stay, effects, drug distribution systems, drug administration and clinical pharmacy services, inpatients, 1691

pharmaceutical services; costs, based upon drug cost plus per-diem fees, 355; costs, pricing, computerized system using a markup and a dose fee, 360; pricing, systems, per-diem, 363

rational therapy; prescribing, effects, length of stay, pyelonephritis patients, 1334

**Hours:** 24-hour service; dosage schedules, pharmacokinetics, role, clinical pharmacists, 1523; hospital pharmacy, survey, 1978, comparison, 1975, 316; outpatients, 1978 survey, university-affiliated hospitals, 1193

**Hydralazine hydrochloride:** tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Hydrochlorothiazide:** interactions; digoxin, monitoring, programs, outpatients, 653

**Hydrogen ion concentration**

cefazolin sodium; injections, effects, membrane filters, in sodium chloride and dextrose in water, 657

cefotaxime sodium; effects, stability, additives, injections, 33

cisplatin; effects, stability, solutions, 38

effects; glycopyrrolate, additives, stability, 508

FreAmine II; decreased, by tetracycline additive, 511

heparin sodium; effects, stability, in dextrose in water and dextrose in sodium chloride, 618

**Hyperalimentation, see Parenteral nutrition**

**Hypotensive agents**

clonidine; overdose, and therapy, review, 906

deserpidine; drug interactions, monitoring, Medicaid patients, 923

dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802; pharmacokinetics, discussion 1222

drug use review; comparison, methods, family-practice clinic, 1665

guanethidine; drug interactions, monitoring, Medicaid patients, 923

hydralazine hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

methyldopa; drug interactions, monitoring, Medicaid patients, 923; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

patients; clinical pharmacists, role, management, 1321

rauwolfia serpentina; extracts, drug interactions, monitoring, Medicaid patients, 923

reserpine; drug interactions, monitoring, Medicaid patients, 923

## I

**Immunosuppressive agents;** azathioprine; polychondritis, relapsing, therapy, patient, 806

**Incompatibilities**

additives and FreAmine II; discoloration, and precipitation, 511

additives and glycopyrrolate; effects, pH, 508

amphotericin and FreAmine II; discoloration, and precipitation, 511

ampicillin sodium and FreAmine II; discoloration and precipitation, 511

charcoal activated and sucrose; adsorption, sodium salicylate, reduced, in vitro, 797

chloramphenicol sodium succinate and glycopyrrolate, effects, pH, 508

dexamethasone sodium phosphate and glycopyrrolate, effects, pH, 508

diazepam and glycopyrrolate; effects, pH, 508

diazepam and plastics; injections, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

dimenhydrinate and glycopyrrolate; effects, pH, 508

FreAmine II and additives; discoloration, and precipitation, 511

glycopyrrolate and additives, effects, pH, 508

methohexital sodium and glycopyrrolate; effects, pH, 508

pentazocine lactate and glycopyrrolate; effects, pH, 508

pentobarbital sodium and glycopyrrolate; effects, pH, 508

plastics and diazepam; injections, i.v., in dextrose, sodium chloride, Ringer's injection, and Ringer's injection lactated, 505

Ringer's injection lactated and glycopyrrolate, effects, pH, 508

secobarbital sodium and glycopyrrolate; effects, pH, 508

sodium bicarbonate and glycopyrrolate; effects, pH, 508

sucrose and charcoal activated; adsorption, sodium salicylate, reduced, in vitro, 797

tetracycline hydrochloride and FreAmine II; discoloration, and precipitation, 511

thiopental sodium and glycopyrrolate; effects, pH, 508

**Index Medicus;** drug information; comparison, other services, 1215

**Indomethacin;** gout; and hyperuricemia, therapy, discussion, 497

**Industry, pharmaceutical;** drugs; storage, and stability, use of lot numbers, 1545

**Information;** reprints; requests, response rates, 1219

**Injections**

cefazolin sodium; filters, membrane, effects, concentration and particulate contamination, in sodium chloride and dextrose in water, 657

diazepam; i.v. incompatibilities, plastics, in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

doxorubicin hydrochloride; stability, effects, temperature, 1536

filters; membrane, inline, air-venting, effects, air flow, administration sets, 749

heparin; rates, methodology, comparison, pharmacokinetic model and patient weight, 782

heparin sodium; vehicles, stability, dextrose in water or sodium chloride, 618

insulin; dosage, low, continuous, availability, effects of solution type, container, administration set, concentration and rate, 330

intravenous; contamination, admixtures, during sterility testing, 1493; contamination, effect, membrane final-filter pore size on survival, rabbits, 1711; contamination, microbiological, determination, membrane filter set, 1202; equipment, comparison, systems, contamination, costs and workload, 1497; flow, rates, clamps, comparison, electronic controller, 1090; osmolarity, methods, 1357; phlebitis, effects, inline membrane final filters, postoperative patients; 1355

nitroglycerin; i.v. extemporaneous, stability, 173

insulin; availability; injections, low-dose, continuous, effects of solution type, container, administration set, concentration and rate, 330

**Interactions;** tetracycline and antacids; monitoring, progress, outpatients, 653

**International Pharmaceutical Abstracts;** drug information; comparison, other services, 1215

**Intravenous therapy;** toxicity; phlebitis, effects, inline membrane final filters, postoperative patients, 1355

**Inventory**

control; hospital pharmacy, computerized system, 360

drugs; hospitals, U.S., General Accounting Office report, 1171

hospital pharmacy; computers, use, 1197; drugs, storage and stability, use of lot numbers, 1545; effects, decentralized operating room pharmaceutical services, 1342; statistics, 1978 survey, 650

**Ions;** stannous; stability, stannous chloride dihydrate, comparison, commercial and extemporaneous radio-pharmaceutical kits, 1370

**Iowa Drug Information Service;** drug information; comparison, other services, 1215

**Ipecac;** effects; electrolytes, blood levels, comparison, lavage patients, 1336

## J

**Journal References,** 96, 241, 381, 522, 686, 817, 972, 1112, 1237, 1410, 1570, 1714

**Journals;** articles; reprints, requests, response rates, 1219

## K

**Kanamycin sulfate;** incompatibilities; cefotaxime sodium, lack, in vitro, 33

**Kaolin**

combination, pectin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097

diarrhea; therapy, discussion, 757

**Kinetics**

amoxicillin trihydrate; stability, temperature, effects, reconstituted unit dose, 209

ampicillin; stability, temperature, effects, reconstituted unit dose, 209

penicillin V potassium; stability, temperature, effects, reconstituted unit dose, 209

## L

**Lactobacillus acidophilus**

combination, *Lactobacillus bulgaricus*; prophylaxis, ampicillin-induced diarrhea, patients, 754

diarrhea; therapy, discussion, 757

**Lactobacillus bulgaricus;** combination, *Lactobacillus acidophilus*; prophylaxis, ampicillin-induced diarrhea, patients, 754

**Law Notes,** 85, 226, 1230

**Laws**

Drug Regulation Reform Act of 1979; provisions, Kennedy bill, 1230

pharmacy; inspections, warrantless, discussion, 85

**Legislation;** drugs; purchasing, and inventory, hospitals, U.S., General Accounting Office report, 1171

**Letters,** 22, 151, 295, 440, 593, 736, 881, 1024, 1155, 1300, 1464, 1651

**Levamisole hydrochloride;** sarcoidosis; therapy, discussion, 351

**Lidocaine hydrochloride**

antidotes; poisoning, digitoxin, patients, 92

incompatibilities; cefotaxime sodium, lack, in vitro, 33

withdrawal; lack, ventricular arrhythmia, myocardial infarction patients, 778

**Light;** cisplatin; stability, solutions, 38

**Literature**

American Society of Hospital Pharmacists; topics, 1967-1978, Midyear Clinical Meeting papers, 1372

journals; articles, reprints, response rates, 1219

**Lithium carbonate;** information; comparison, services, 1215

**Loperamide;** diarrhea; therapy, discussion, 757

## M

**Magnesium hydroxide**

combination, aluminum hydroxide; absorption, oral aminophylline, effects, patients, 1059

combination, aluminum hydroxide, simethicone; tablets, equivalency, generic, acid reactivity, in vitro, 660

**Mannitol;** Reye's syndrome; therapy, review, 757

**Manpower;** pharmacists, hospital; outpatients, services, 1978 survey, university-affiliated hospitals, 1193

**Manufacturing**

admixtures; injections, plastic containers, dextrose in water, time studies, contamination rates, 513

cardioplegic solutions, hospital pharmacy, 1361

drugs; industry, pharmaceutical, storage, and stability, hospital pharmacy, use of lot numbers, 1545

nitroglycerin; hospital pharmacy, i.v. formulation stability, 173

**Mechanism of action**

amphotericin B; review, 1326

clotrimazole; review, 1326

dextran 70; adverse reactions, thrombotic thrombocytopenic purpura patient, 89

digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968

erythromycin; and derivatives, review, 1185

flucytosine; review, 1326

griseofulvin; review, 1326

heparin; thrombopenia, patients, 1561

methenamine hippurate; review, 1509

methenamine mandelate; review, 1509

miconazole nitrate; review, 1326

nalidixic acid; review, 1071

nitrofurantoin; review, 342

nystatin; review, 1326

oxolinic acid; review, 1077

sulfamethoxazole, combination, trimethoprim; review, 893

trimethoprim, combination, sulfamethoxazole; review, 893

**MEDLINE;** drug information; comparison, other services, 1215

**Meeting Dates,** 113

**Meperidine;** interactions; phenothiazines, potentiation, review, 633

**Meperidine hydrochloride**

dosage forms; adulteration, visual, colorimetry and UV spectrometry, 1094

hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Mestranol;** combination, norethindrone; ischemic bowel disease, patient, 1103

**Metabolism;** spironolactone; metabolites, canrenone, blood levels, following neomycin sulfate, patients, 1701

**Metaraminol bitartrate;** hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Methenamine hippurate;** mechanism of action; pharmacokinetics, effects, adverse reactions, dosage, review, 1509

**Methenamine mandelate;** mechanism of action; pharmacokinetics, effects, adverse reactions, dosage, review, 1509

**Methicillin;** toxicity; skin, patients, 609

**Methodology**

aminoglycosides; blood levels, rational therapy, pharmacists, role, 1080

antibiotics; drug use review, hospitals, systems, problems, 376



contamination; microbiological, determination, i.v. injections and administration sets, 1202  
 drug information; systems, evaluation, 793  
 drug interactions; outpatients, monitoring, programs, 653  
 drug use review; hypotensive agents, family-practice clinic, 1665  
 drugs; stability, hospital pharmacy, use of lot numbers, 1545; therapy, systematic problem solving approach, 798  
 furosemide; dosage schedules, comparison, once and twice daily, excretion, patients, 68  
 heparin; injections, rates, comparison, patient weight and pharmacokinetic model, 782  
 hypotensive agents; dosage schedules, patient individualization, pharmacokinetics, and pharmacodynamics, 802; dosage schedules, pharmacokinetics, discussion, 1222  
 patient information; profile development, from drug-charging records, hospitals, 1347  
 prescribing; physicians, rational therapy, discussion, 1099  
 theophylline; dosage, oral, using clearance rates following i.v. infusion, patients, 66  
 warfarin sodium; dosage, prothrombin time, patients, 1351  
**Methohexital sodium**; incompatibilities; glycopyrrolate, effects, pH, 508  
**Methotrexate**; sarcoidosis; therapy, discussion, 351  
**Methyldopa**  
 drug interactions; monitoring, Medicaid patients, 923  
 tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Miconazole nitrate**; mechanism of action; toxicity, dosage availability and costs, review, 1326  
**Minoxidil**; dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802  
**Models**  
 administration sets; flow, rates, 338  
 dyphylline; pharmacokinetics, patients, 1179  
 pharmacokinetics; heparin, methodology, injection rates, 782  
 reimbursement; clinical pharmaceutical services, third-party, 1548  
**Moisture**; dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539  
**Morphine**; diarrhea; therapy, discussion, 757  
**Morphine sulfate**; interactions; phenothiazines, potentiation, review, 633  
**Mydratics**; homatropine hydrobromide; solutions, ophthalmic, polychondritis, relapsing, therapy, patients, 906

## N

**Nalidixic acid**; mechanism of action; pharmacokinetics, interactions, dosage, adverse reactions, review, 1071  
**Naproxen**; blood levels; hemodialysis, effects, patients, 1567  
**Neomycin sulfate**; effects; spironolactone, availability, patients, 1701  
**Netilmicin**; and ticarcillin; toxicity, ear, leukopenic patients, 1083  
**New Periodicals**, 110, 252, 846, 1119, 1428, 1508  
**News**, 122, 258, 408, 563, 706, 852, 992, 1128, 1272, 1435, 1612, 1728  
 Additional evidence published in support of changing i.v. administration sets every 48 hours rather than every 24 hours, 1612  
 American Association of Colleges of Pharmacy members meet with congressional aides, 1133  
 American Medical Association panel issues guidelines on parenteral use of essential trace elements, 993  
 American Pharmacological Association Remington Medal awarded to Eugene White, 564  
 American Society of Consultant Pharmacists-Lilly publish results of survey on long-term care pharmacy operations, 1132  
 American Society of Consultant Pharmacists surveys unit dose reimbursement policies of Medicaid programs, 1442  
 American Society of Hospital Pharmacists and the American Hospital Association develop patient education workshops, manuals, 564  
 Appointments and promotions, 124, 263, 416, 569, 710, 859, 998, 1133, 1278, 1444, 1613, 1731  
 Archambault, George F., 861; Arrington, David M., 1613; Baumgartner, R. Paul Jr., 128; Bell, J. Edward, 1133; Bingham, Johnnie Jr., 1613; Blackburn, Daryl, 1731; Bratland, Gary L., 1614; Bryant, Stephen H., 859; Burke, W. Arthur, 1613; Card, Vincent, 1731; Chaikin, Philip, 710; Chapman, Jeff, 710; Ciullo, Steven J., 416; Colangelo, Anthony, 1133; Crimmon, Miles L., 1731; Croft, Al, 416; Culkin, Thomas T., 263; Cupit, Gary C., 998; Dahlin, Patricia A., 1278; Davern, Paul, 569; De-

Leon, Richard F., 998; DelVecchio, Gilda Jo, 710; DiBona, John R., 1613; DiMattia, Philip, 1613; Doutre, William H., 1133; Duncan, Edgar, 1444; Edgerton, Walter L., 416; Farris, Philip W. Jr., 1731; Feldman, Marvin J., 569; Fink, Joseph L. III, 1613; Finkelstein, Burt, 1613; Fishman, Doris A., 1613; Flesh, Judy S., 1731; Gertraud, Robert J., 1613; Gever, Larry N., 1278; Gibson, Ernest L., 416; Glorioso, John A. Jr., 263; Goldstein, Eric, 1731; Grady, Lee T. (Tim), 416; Greene, Ronald, 1731; Grimm, Robert L., 569; Haley, Nancy Jane, 1444; Hamet, Harry, 1613; Hamilton, Stephen F., 1731; Hansen, Carolee, 1731; Harris, William, 1731; Hopeff, Alan W., 1613; Hurlow, George D., 1444; Jewett, Christina, 859; Jozefczyk, Arthur D., 1444; Juhl, Randy P., 1731; Kaul, Alan, 1613; Kleinberg, Michael L., 1444; Klepyk, James C., 1444; Koeller, Jim, 1133; Kubica, Anthony J., 1278; Lancaster, William J., 1613; Leavitt, Linwood S., 1282; Lerario, Donald, 1278; Lima, John, 569; Loeb, Allan J., 1613; Lopez, Larry M., 1731; Lowenthal, Werner, 128; Mannone, Louis J., 1444; Marquardt, Karl W., 861; Marsh, David A., 416; McAllister, James, 1731; Means, Berry J., 1613; Meyers, John C., 1278; Miranda, Richard, 1731; Moore, Timothy D., 128; Morris, Stuart N., 859; Musia, Mark, 1731; O'Brien, William E., 1282; Olen, Marriakay, 1731; Paiva, Kenneth B., 861; Paulson, Patrick T., 710; Pearson, Warren, 1613; Pelletier, Mark, 1731; Pevonka, M. Peter, 1613; Pollhammer, Richard W., 1614; Pope, Patricia Ann, 263; Powell, Stephen, 1613; Probst, Edward H., 859; Roehrl, Pamela, 263; Roffe, Bruce D., 710; Rosenthal, Alan, 1444; Rudd, Christine, 1731; Russell, Wayne, 1731; Ryan, Patrick B., 124; Saito, Thomas E., 124; Schmadel, Linda, 710; Schneider, Philip J., 128; Scratow, Renee R., 1614; Silkey, Werner G., 124; Spears, Jeffrey B., 1133; Steckel, Steven D., 1613; Summerfield, Marc R., 416; Tanazevich, Alexander, 998; Tanner, David J., 859; Traub, Scott L., 416; Trudeau, Terry, 264, 998; Turk, James B., 859; Vinson, Michael C., 1278; Vitale, Paul J., 1613; Wainwright, C. Francis, 859; Weiss, Elvira, 264; Williams, Ronald D., 416; Zook, Susan, 859  
 AV program available on plastic bag system preparation of TPN solutions, 263  
 The business of health, 408  
 Capitation, technicians and specialty certification issues acted on by AACP House, 1435  
 Certain British hospitals reduce the number of antibiotics used and report cost savings, 1129  
 Checklist helps patients keep track of their medications, 996  
 College-based technician training programs: Producing without planning?, 992  
 Columbia University recognized as comprehensive cancer center, 708  
 Congressman Rogers recognized for health service by AACP, 124  
 Detailing policies in hospitals surveyed, 1129  
 Device reporting program expanded to hospitals, 1444  
 Estrogen prescribing practices scrutinized at NIH conference, 1728  
 FDA gives nonprescription status to five drug ingredients, 565  
 FDA objectives for 96th Congress outlined by general counsel, 854  
 Feasibility of reopening southwest thyroid cancer study assessed, 566  
 Federal funding extended for study of patient education programs, 1613  
 Food safety regulation panel urges Congress to revamp regulatory statutes, 706  
 Group purchasing of pharmaceuticals cuts millions from health care costs, 1128  
 Grover Bowles receives APhA Hugo H. Schaefer Award, 564  
 Guidelines for selection, processing and use of LVP containers and closures approved, 1132  
 Health care fellowships available through Hospital Research and Educational Trust, 1276  
 HEW report addresses health, promotion and disease prevention, 1435  
 Hospital formularies: How selective are they? 563  
 International Congress of Pharmaceutical Sciences to meet in September, 706  
 Investigational drug protocols made available to hospital pharmacists by Merck Sharp & Dohme, 416  
 The life of a pharmacist (who happens to be a Vietnamese refugee), 1272  
 Lilly develops educational program on Dobutrex for pharmacists, 996  
 Lilly surveys for trends in hospital pharmacy, 1282  
 Mandatory patient counseling regulations have little effect on hospital pharmacists, 410  
 Medical charts shown to be deficient in recording outpatient drug therapy, 706  
 Medication awareness program available from APhA, 996  
 Meetings and continuing education programs, 128, 264, 416, 569, 710, 861, 998, 1133, 1282, 1444, 1732  
 Model for hypertensive services developed by New York students, 998

More unit dose products are forecast, 1728  
 National Association of Boards of Pharmacy approves recommendations on patient product information, information transfer, institutional pharmacy inspection form, 1444  
 New Clinical Science Center opens at University of Wisconsin, 708  
 New Medical University of South Carolina will prepare students for industrial pharmacy, 856  
 New monographs, title changes and revisions in fifth USP-NF supplement, 414  
 New Voluntary Effort Chartbook reviews health care, hospital cost issues, 1132  
 News briefs, 128, 264, 418, 570, 710, 862, 1000, 1134, 1284, 1445, 1614, 1733  
 American Foundation for Pharmaceutical Education, 570; Anderson, Janice D., 570; Anderson, Joanne, 1134; Applied Therapeutics for Clinical Pharmacists, 1734; Auger, Robert R., 418; Bair, Jan N., 1614; Barger, Robert C., 1614; Beckerman, Joseph H., 862; Bellinger, Robert E., 264; Bergen, John V., 1734; Bjerk, Paul G., 418; Boots Pharmaceuticals, Inc., 710; Breast Cancer Digest, 1446; Bryant, Albert, 862; Byrum, Woodrow R., 714; Cady, Thomas E., 1446; College of Pharmacy, University of Illinois at the Medical Center, 710; Cumulative Index of Hospital Literature, 1975-1977, 714; Dembicki, Eugene L., 128; Elenbaas, Robert M., 128; Fleming, Marjorie L., 128; Florey, Klaus G., 264; Freedman, George L., 1614; Goyette, Gordon F. Jr., 1614; Granat, Alan L., 714; Harding, Roland F., 1000; Harmon, Roger, 1134; Home parenteral nutrition, 1134; Hospital cost containment through operations management, 1445; Icaza, Luis A., 862; Institute for Brain Function Research, 1446; Ivers-Lee, 1446; Johnson, Bentley N., 1445; Kansas Council of Hospital Pharmacists, 1000; Kessler, Gunter Karl, 1134; Kleinman, Larry M., 1134; Latiolais, Clifton J., 1284; Levy, Gerhard, 1134; Lifemark Corporation, 1446; Eli Lilly and Company, 1000; Macy, S. A., 1445; Manufacturer disclosure '79, 1445; Massey, Beverly Kay, 862; McKesson Drug Company, 1734; McLaugherty, Larry, 1134; Medic Alert Foundation International, 1133; Medical Information Ltd., 1445; Mehl, Barnard, 1000; Michigan Department of Mental Health, 570; Miller, Jacob W., 1734; National Conference on High Blood Pressure Control, 1445; National Eye Institute, 418; Neutron Products, Inc., 1445; O'Brien, William P., 418; Orange County (California) Society of Hospital Pharmacists, 1445; Pharmacy technician training program, 1284; Pharmacy school admission requirements, 264; Robayo, Juan R., 1445; San Fernando-Ventura Society of Hospital Pharmacists, 1133; Sandusky, Ray, 1614; Scientific Bases for Identifying Potential Carcinogens and Estimating Their Risk, 714; Sewell, Winifred, 1134; Shaw, Donna M., 1614; Skolaut, Milton W., 1133; Soloth, Art, 714; Sondecke, Glenn A., 418; Sorby, Donald L., 128; South Dakota Society of Hospital Pharmacists, 418; Sramek, John J., 714; State board of newsletter project, 1446; Stetler, C. Joseph, 1134; Stewart, Nathaniel, 1446; Stinebaugh, Ernest H., 1734; Swartz, Allan J., 1734; Tanja, Jon J., 128, 862; Thomas Jefferson University Hospital, 1446; Timberlake, Claude V., 1733; Tornatore, Frank L., 714; "Traditional Japanese Medicine and Its Graphics", 570; Trissel, Lawrence A., 1134; University of California at San Francisco School of Pharmacy, 1734; University of Connecticut, 714; Wells, Patrick R., 570; Zeisler, John, 862; Zenk, Karin, 1445; Zoloth, Art, 714; Zupko, Arthur G., 1000, 1134  
 Nominations open for service area experts on USP Committee of Revision, 854  
 North Carolina task force recommends expanded role for pharmacist, 123  
 Nursing Practice Advisory Panel formed to review USP publication, 710  
 156 name changes for 1980 USP XX-NF XV, 1438  
 Pan-Pacific conference is stop on ASHP tour, 1730  
 Pharmacist prescribing being pursued in state legislatures, 258  
 Physicians found to be unaware of hospital charges for drugs and services, 1612  
 Program for cost-saving i.v. antibiotic therapy at home reported, 993  
 Report reviews status of pharmacy: projects surplus by mid-1980s, 261  
 Scientists review status of pertussis vaccine, 124  
 Shared hospital services increase, 1730  
 Standards of pharmacy practice published by AACP and APhA, 854  
 Study questions necessity of daily change of infusion administration sets, 1129  
 Study reveals overuse of antibiotics for prophylaxis, 1612  
 Study shows drug product selection seldom used in Florida, 565  
 Study shows physicians underestimate cost of health services, 856  
 Survey of families reveals lack of coherent health philosophy, 1440  
 The Swine Flu Affair: Good reading and preventive

## Index

medicine for future decision-making, 563  
 Thumbs down on federal regulation of hospital costs—views of five former assistant secretaries for health, 852  
 Unit dose at the VA caught in bureaucratic snarl, 122  
 Updated report on the dialysis and hemoperfusion of poisons and drugs available, 566  
 USP and FDA establish antibiotic monograph subcommittee, 1444  
 Wisconsin law allows optometrists to use diagnostic drugs, 859  
 Women pharmacists needed for vocational interest study, 414  
**Nitrofurantoin**  
 information; comparison, services, 1215  
 therapy; review, 342  
**Nitroglycerin**; injections; i.v. extemporaneous, stability, 173  
**Norethindrone**; combination, mestranol; ischemic bowel disease, patient, 1103  
**Nurses**  
 assistants; pharmacy, students, internships, emphasis on nursing assistant and medication administration through nursing service, 791  
 education; continuing, one-day program, by pharmacists, 44  
 injections; workload; i.v., comparison systems, preparation, 1497  
 role; pharmaceutical services, decentralized, without satellites, 1513  
 warfarin; education, patients, hospitals, 219  
**Nystatin**; mechanism of action; toxicity, dosage availability and costs, review, 1326

**O**

**Osmolarity**; solutions; i.v. and parenteral nutrition methods, 1357  
**Oxacillin**; toxicity; skin, patients, 609  
**Oxolinic acid**; mechanism of action; pharmacokinetics, dosage, adverse reactions, review, 1077  
**Oxycodone**; combination, acetaminophen; therapy, symptoms, folic acid allergies, patient, 1565  
**Oxyphenbutazone**  
 gout; and hyperuricemia, therapy, discussion, 497  
 sarcoidosis; therapy, discussion, 351

**P**

**Package inserts**; patients; Drug Regulation Reform Act of 1979, provisions, Kennedy bill, 1230; regulations, FDA, pharmacist's responsibility, 226  
**Packaging**  
 amoxicillin trihydrate; unit dose, reconstituted, temperature, effects on stability, 209  
 ampicillin; unit dose, reconstituted, temperature, effects on stability, 209  
 nitroglycerin; injections, i.v., hospital pharmacy, 173  
 penicillin V potassium; unit dose, reconstituted, temperature, effects on stability, 209  
 unit dose; syringes, oral, plastic, various temperatures, effects on penicillin V potassium stability, 205  
**Paget's disease**; calcitonin; self-medication, costs, effects, clinical pharmacists training programs, inpatients, 1527  
**Papaverine hydrochloride**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Parasympatholytic agents**; propantheline bromide; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Parenteral nutrition**  
 additives; stability, and incompatibilities, FreAmine II, 511  
 adverse reactions; solutions, fat-free, patient, 230  
 amino acids; concentration, formulary change, hospitals, 57  
 policies and procedures; manuals, development, review, 817  
 programs; pharmacists, hospital, role, 648  
 self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527  
 solutions; osmolarity, methods, 1357  
 soybean oil; therapy, patients with fatty-acid deficiencies, 230  
 therapy; pharmacists, role, patient outcome and costs, 785  
**Parenterals**, see **Injections**  
**Particles**  
 amphotericin B; stability, in FreAmine II, 511  
 ampicillin sodium; stability, in FreAmine II, 511  
 contamination; cefazolin sodium, injections, in sodium chloride and dextrose in water, 657  
 FreAmine II; stability, with additives, 511  
**Patient information**  
 consultation; clinical pharmacists, family-practice office,

912; parenteral nutrition, pharmacists, hospital, role, 648; pharmacists, role, clinics, screening and prescribing, ambulatory patients, 916; toxicity, skin, monitoring, hospitals, patients, 609  
 deferoxamine; pharmacists, hospital, consultation, Cooley's anemia patients, 788  
 diabetes mellitus; clinical pharmacists, role, management, 1321  
 hypertension; clinical pharmacists, role, management, 1321  
 medical histories; anticoagulants, pharmacists, hospital, role, ambulatory clinic, 645  
 package inserts; Drug Regulation Reform Act of 1979, provisions, Kennedy bill, 1230; regulations, FDA, pharmacist's responsibility, 226  
 profile; development, from drug-charge records, hospitals, 1347; outpatients, survey, 1978, university-affiliated hospitals, 1193; pharmaceutical services, decentralized, without satellites, 1513  
 self-medication; clinical pharmacists, role, cost savings, inpatients, 1527  
 warfarin; hospitals, pharmacists and nurses, 219  
**Patients**  
 ambulatory; anticoagulants, clinic, pharmacists' role, 645; clinics, pharmacists, role, screening and prescribing, 916  
 education; adrenalectomy, by hospital pharmacist, 1212; theophylline, audiovisual, with and without pharmacists present, 63; warfarin, hospitals, pharmacists and nurses, 219  
 health care; quality, effects, clinical pharmacy services, 325  
 inpatients; length of stay, effects, drug distribution systems, drug administration and clinical pharmacy services, 1691  
 outpatients; hospital pharmacy, planning and design, facilities, modernization, 371; interactions, monitoring, 653; pharmaceutical services, survey, 1978, university-affiliated hospitals, 1193  
**Pectin**  
 combination, kaolin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
 diarrhea; therapy, discussion, 757  
**Pediatrics**; poisoning; pharmacists, consultation, clinical toxicology service, 1087  
**Penicillin G**; toxicity; skin, patients, 609  
**Penicillin G potassium**; hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
**Penicillin V potassium**; stability; syringes, oral, plastic, various temperatures, 205  
 temperature, freezing, effects, reconstituted unit dose, 209  
**Pentaerythritol tetranitrate**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Penitoxone lactate**; incompatibilities, glycopyrrolate, effects, pH, 508  
**Pentobarbital sodium**; incompatibilities; glycopyrrolate, effects, pH, 508  
**Personnel**; admixtures; injections, education, control, quality, 605  
**Personnel, pharmacy**  
 disaster planning; role, 1337  
 evaluations; methods, 187  
 hospitals; performance, appraisal, methods, 1676  
 supportive; technicians, decentralized services without satellites, 1513; technicians, training programs, 1533; technicians, workload, i.v. injections, comparison, systems, 1497; workload, comparison, two methods, 59  
**Pharmaceutical education**, see **Education, pharmaceutical**  
**Pharmaceutical services**  
 decentralized; hospitals, without satellites, 1513; operating room, establishment, 1342  
 hospitals; effects, adverse reactions, length of stay, inpatients, 1691; 1978, comparison, 1975, survey, 316; pricing, computerized system using a markup and a dose fee, 360; professional fees, based upon medication administration record, 365; strategy, increased demand, 1553  
 professional fees; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, pricing, based upon per diem drug costs, 363  
**Pharmacists**  
 Harvey A. K. Whitney Lecture Award; 1978, patient, 311  
 package inserts; regulations, FDA, 226  
 parenteral nutrition; therapy, role, patient outcome and costs, 785  
 reimbursement; clinical pharmacy, services, models, 1548; costs, savings, inpatients, self-medication programs, 1527; education, adrenalectomy patients, 1212; third-party, dosage schedules, pharmacokinetics, 1523  
 role; clinics, screening and prescribing, ambulatory patients, 916; nurses, continuing education, one-day program, 44  
**Pharmacists, hospital**  
 anticoagulants; role, clinic, ambulatory, development, operation, patient management protocols and educa-

tion, 645  
 consultation; deferoxamine, self-medication, patients, 788; poisoning, pediatrics, clinical toxicology service, 1087  
 disaster planning; role, 1337  
 drug use review; heparin sodium and warfarin sodium, embolism, thrombosis and thrombophlebitis, 214  
 education; continuing, decentralized staff program, 50; patients, adrenalectomy, 1212; patients, effects, audiovisual aids for theophylline information, 63  
 Great Britain; history, 492  
 parenteral nutrition; programs, role, 648  
 performance; appraisal, methods, 1676  
 role; aminoglycosides, blood levels, rational therapy, 1080; pharmaceutical services, decentralized, without satellites, 1513  
 toxicity; skin, monitoring, patients, 609  
 warfarin; education, patients, hospitals, 219  
 workload; comparison, two methods, 59; computers, word-processing machines compared, 1529; time studies, productivity evaluation, 201  
**Pharmacokinetics**  
 bretylium tosylate; review, 1189  
 butorphanol tartrate; review, 1683  
 cefamandole nafate; review, 1503  
 cefoxitin sodium; review, 1503  
 dosage schedules; clinical pharmacists, development and reimbursement, 1523  
 dyphylline; patients, 1179  
 erythromycin; and derivatives, review, 1185  
 gentamicin; ascitic patients, 1704  
 heparin; dosage schedules, effects, costs, tests and errors, 920  
 hypotensive agents; dosage schedules, discussion, 1222; dosage schedules, patient individualization, methodology, 802  
 lidocaine hydrochloride; withdrawal, myocardial infarction patients, 778  
 methenamine hippurate; review, 1509  
 methenamine mandelate; review, 1509  
 models; heparin, methodology, injection rate, 782  
 nalidixic acid; review, 1071  
 oxolinic acid; review, 1077  
 services; costs, hospitals, 368  
 sulfamethoxazole, combination, trimethoprim; review, 893  
 trimethoprim, combination, sulfamethoxazole; review, 893  
**Pharmacokinetics in Drug Therapy**, 802, 1222  
**Pharmacology**; nitrofurantoin; review, 342  
**Pharmacy**  
 clinical, see **Clinical pharmacy**  
 education, see **Education, pharmaceutical**  
 laws; inspections, warrantless, discussion, 85  
 personnel, see **Personnel, pharmacy**  
 students; internships, emphasis on nursing assistant and medication administration through nursing service, 791  
**Pharmacy, institutional**; patients; ambulatory, clinic, pharmacists, role, screening and prescribing, 916  
**Pharmacy, institutional, hospital**  
 admixtures; injections, containers, plastic, dextrose in water, compounding times and contamination rates, 513  
 amino acids; concentration, parenteral nutrition solutions, formulary change, 57  
 cefazolin; prescribing, control, programs, 1055  
 charges; drugs, based upon medication administration record, 365  
 computers; comparison, word-processing machines, 1529; files, multifunctional drug, development, 1197  
 costs; pharmacokinetics, services, 368  
 decentralized; emergency room, costs, 52  
 disaster planning; personnel, role, 1337  
 drug information; services, effects, clinical pharmacy, 1520  
 drugs; inventory, storage and stability, use of lot numbers, 1545  
 education; American Society of Hospital Pharmacists, topics, 1967-1978, Midyear Clinical Meeting papers, 1372  
 education, pharmaceutical; residencies, screening and selection procedure, 194  
 injections; i.v., equipment, comparison, systems, contamination, costs and workload, 1497  
 outpatients; services, survey, 1978, university-affiliated, 1193  
 personnel; evaluations, methods, 178  
 pharmaceutical services; 1978, comparison, 1975, survey, 316; pricing, per-diem system, 363  
 planning and design; outpatients, ambulatory, facilities, modernization, 371  
 policies and procedures; manuals, admixture services, parenteral nutrition, development, review, 517  
 reimbursement; education, adrenalectomy patients, 1212  
 services; decentralized, operating room, and recovery room, establishment, 1342; decentralized, without satellites, 1513



statistics; purchasing, and inventory, 1978 survey, 650  
workload; pharmacists, and supportive personnel, comparison, methods, 59

**Phenobarbital**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Phenobarbital sodium**; hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Phenothiazines**; analgesics and antipyretics; rational therapy, review, 633

**Phenylbutazone**; gout; and hyperuricemia, therapy, discussion, 497

**Phenytoin**  
information; comparison, services, 1215  
toxicity; skin, patients, 609

**Phenytoin sodium**  
antidotes; poisoning, digitoxin, patients, 92  
capsules; stability, storage, counting machine, spectrometry and colorimetry, 1539  
hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Physicians**  
information; effects, clinical pharmacist consultation, family-practice office, 912  
prescribing; albumin, drug use review, hospitals, 1205, cefazolin, control, programs, hospital, 1055; effects, clinical pharmaceutical services, hospitals, 1553; effects, length of hospital stay, pyelonephritis patients, 1334; rational therapy, discussion, 1099

**Planning and design**; hospital pharmacy; outpatients, ambulatory, facilities, modernization, 371

**Plastics**  
catheters; toxicity, thrombosis, patients, effects, physical characteristics, 1707  
containers; admixtures, injection, dextrose in water, compounding times and contamination rates, 513; effects, stability, extemporaneous nitroglycerin i.v. injections, 173  
incompatibilities; diazepam, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505  
syringes; penicillin V potassium, oral, stability, 205

**Pneumococcal vaccines**; review, 773

**Poisoning**  
digitoxin; antidotes, patients, 92  
drugs; antidotes, effects, electrolyte blood levels, patients, 1366  
pediatrics; pharmacists, consultation, clinical toxicology service, 1087

**Polarography**; ions; stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370

**Polyvinyl chloride**; containers; effects, insulin, availability, low-dose continuous injections, 330

**Pore size**; filters; membrane, inline, final, effects, survival, following injections of contaminated i.v. fluids, rabbits, 1711

**Potassium chloride**  
antidotes; poisoning, digitoxin, patients, 92  
solutions, osmolality, methods, 1357

**Potassium iodide**; toxicity; skin, patients, 609

**Precipitates**; PreAmine II; injections, additive stability, 511

**Prednisolone acetate**; solutions, ophthalmic; polychondritis, relapsing, therapy, patients, 806

**Prednisone**  
polychondritis, relapsing; therapy, patient, 806  
purpura; thrombotic thrombocytopenic, therapy, patient, 89

**Prescriptions**  
antibiotics; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
anti-infective agents; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
cefazolin; prescribing, control, programs, hospital, 1055  
costs; emergency room, decentralized pharmacy service, 52  
drug use review; hypotensive agents, comparison, methods, family-practice clinic, 1665  
pricing; outpatients, 1978 survey, university-affiliated hospitals, 1193

**Preservatives**  
benzoic acid; effects, adulteration tests on meperidine hydrochloride, 1094  
m-cresol; effects, adulteration tests on meperidine hydrochloride, 1094  
sodium acetate; solutions, protein hydrolysates and dextrose, 1672

**Probenecid**; gout; and hyperuricemia, therapy, discussion, 497

**Professional fees**; pharmaceutical services; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, based upon medication administration record, 365; hospitals, computerized system using a markup and a dose fee, 360; hospitals, pricing, based upon per-diem drug costs, 363

**Promethazine hydrochloride**; hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Propantheline**; diarrhea; therapy, discussion, 757

**Propantheline bromide**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Propranolol hydrochloride**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Protein hydrolysates**; and dextrose; solutions, sodium acetate, preservatives, 1672

**Psychotherapeutic agents**  
lithium carbonate; information, comparison, services, 1215  
toxicity; extrapyramidal disorders, prophylaxis, antiparkinson agents, patients, 641

**Purchasing**  
drugs; hospital pharmacy, computers, use, 1197; hospitals, survey, 1978; comparison, 1975, 316; hospitals, U.S., General Accounting Office report, 1171  
hospital pharmacy; statistics, 1978 survey, 650

**Purpura**  
dipyridamole; thrombotic thrombocytopenic, therapy, patient, 89  
prednisone; thrombotic thrombocytopenic, therapy, patient, 89

## Q

**Quality assurance**  
admixtures; injections, methods and procedures, 605  
blood levels; aminoglycosides, monitoring, hospital pharmacists, role, 1080  
drug information; systems, evaluation, 793  
drug therapy; hospitals, systems, problems, 376  
prescribing; aminoglycosides, monitoring, hospital pharmacists, 1209

**Quinidine sulfate**; interactions; digoxin, increased blood levels, patient, 968

## R

**Radiopharmaceuticals**; stannous chloride dihydrate; ions, stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370

**Rational therapy**  
albumin; prescribing, hospitals, 1205  
amikacin; pharmacists, hospital, role, 1209  
aminoglycosides; blood levels, pharmacists, role, 1080  
antibiotics; drug use review, hospitals, systems, problems, 376; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
antidiarrhea agents; review, 757  
anti-infective agents; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
anti-inflammatory agents; review, 622  
antimycotic drugs; review, 1326  
antiparkinson agents; extrapyramidal disorders, prophylaxis, psychotherapeutic agent-induced, patients, 641  
antirheumatic agents; review, 622  
butorphanol tartrate, discussion, 1683  
cefamandole nafate; review, 1503  
cefazolin; control, prescribing, programs, hospital, 1055  
cefazolin sodium; review, 1503  
drugs; methodology, systematic problem-solving approach, 798  
erythromycin; and derivatives, review, 1185  
estrogens; patients, peri- and postmenopausal, review, 1062  
heparin sodium and warfarin sodium; pharmacists, hospital, monitoring, role, 214  
hypotensive agents; drug use review, comparison, methods, family-practice clinic, 1665  
methenamine hippurate; review, 1509  
methenamine mandelate; review, 1509  
nalidixic acid; review, 1071  
oxolinic acid; review, 1077  
phenothiazines; analgesics and antipyretics, review, 633  
physicians; prescribing, discussion, 1099  
pneumococcal vaccines; review, 773  
sulfamethoxazole, combination, trimethoprim; review, 893  
tobramycin; pharmacists, hospital, role, 1209  
tolazoline; clonidine, overdose, review, 906  
warfarin sodium and heparin sodium; pharmacists, hospital, monitoring, role, 214

**Rauwolfia serpentina**; extracts; drug interactions, monitoring, Medicaid patients, 923

**Records**  
drug use review; albumin, prescribing, hospitals, 1205  
drugs; cost, hospitals, use in development of patient drug-use profile, 1347  
medical; hospitals, detention, drug charges, 365; pharmaceutical services, decentralized, without satellites, 1513

**Regulations**  
effects; rational therapy, discussion, 1099  
package inserts; patients, FDA, pharmacist's responsibility, 226

**Reprints**; articles; journals, requests, response rates, 1219

**Rescinnamine**; drug interactions; monitoring, Medicaid patients, 923

**Reserpine**; drug interactions; monitoring, Medicaid patients, 923

**Reye's syndrome**; drugs; therapy, review, 767

**Ringer's injection**; additives; injections, diazepam, i.v., incompatibilities, plastics, 505

**Ringer's injection lactated**  
additives; injections, diazepam, i.v., incompatibilities, plastics, 505  
effects; insulin availability, low-dose continuous injections, 330  
incompatibilities; glycopyrrolate, effects, pH, 508

## S

**Salaries**; personnel, pharmacy; supportive, injections, i.v. comparison, systems, preparation, 1497

**Saliva levels**; dyphylline; patients, 1179

**Sarcoidosis**  
allopurinol; therapy, discussion, 351  
chloroquine; therapy, discussion, 351  
levamisole hydrochloride; therapy, discussion, 351  
methotrexate; therapy, discussion, 351  
oxyphenbutazone; therapy, discussion, 351  
steroids cortico-; therapy, discussion, 351

**Secobarbital sodium**; incompatibilities; glycopyrrolate, effects, pH, 508

**Security**; hospital pharmacy; effects, decentralized operating room pharmacy services, 1342

**Sedatives and hypnotics**; phenobarbital; tablets, stability, storage, counting machine, spectrometry, and colorimetry, 1539

**Simethicone**; combination, aluminum hydroxide, magnesium hydroxide; tablets, equivalency, generic, acid reactivity, in vitro, 660

**Sodium acetate**; preservatives; solutions, protein hydrolysates and dextrose, 1672

**Sodium bicarbonate**  
buffers; cardioplegic solutions, effects, stability, 1361  
incompatibilities; glycopyrrolate, effects, pH, 508

**Sodium carbonate**; buffers; cardioplegic solutions, effects, stability, 1361

**Sodium chloride**  
additives; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, 657; injections, diazepam, i.v., incompatibilities, plastics, 505  
adulteration; meperidine hydrochloride, dosage forms, 1094  
alone and with dextrose; solutions, effects, insulin availability, low-dose continuous injections, 330  
diluent; effects, stability, extemporaneous nitroglycerin i.v. injections, 173  
heparin sodium; stability, 618  
solutions; osmolality, methods, 1357

**Sodium salicylate**; adsorption; charcoal activated, reduced by sucrose, in vitro, 797

**Solutions**  
cisplatin; stability, UV spectrometry, 38  
dextrose; preservatives, sodium acetate, 1672  
heparin; use, cytopathology, bottles, collection of body cavity fluids, 211  
protein hydrolysates and dextrose; preservatives, sodium acetate, 1672

**Solutions, ophthalmic**  
homatropine hydrobromide; polychondritis, relapsing, therapy, patient, 806  
prednisolone acetate; polychondritis, relapsing, therapy, patient, 806

**Soybean oil**; parenteral nutrition; therapy, patients with fatty-acid deficiencies, 230

**Spasmolytics**  
aminophylline; absorption, excretion, blood levels, lack, effects, aluminum hydroxide, combination, magnesium hydroxide patients, 1059  
dyphylline; pharmacokinetics, patients, 1179  
papaverine hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
theophylline; information, comparison, services, 1215; tablets, sustained-action, dosage schedules, blood levels, asthmatic children, 1698

**Spectrometry**; dosage forms; tablets, and capsules, storage, counting machine, effects on stability, 1539

**Spectrometry, ultraviolet**  
cisplatin; solutions, stability, 38  
meperidine hydrochloride; dosage forms, adulteration, 1094  
penicillin V potassium; stability, syringes, oral, plastic, various temperatures, 205

**Spirolactone**

availability; effects, neomycin sulfate, patients, 1701  
tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Stability**

additives and FreAmine II; discoloration, and precipitation, 511  
amoxicillin trihydrate; temperature, freezing, effects, reconstituted unit dose, 209  
amphotericin B; additives, FreAmine II, incompatibilities, 511  
ampicillin; temperature, freezing, effects, reconstituted unit dose, 209  
ampicillin sodium and FreAmine II; particles, 511  
antibiotics; injections, FreAmine II, incompatibilities, 511  
ascorbic acid; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
aspirin; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
cardioplegic solutions; effects, albumin and buffers, 1361  
cefazolin sodium; injections, effects, membrane filters, on concentration and particle contamination, in sodium chloride and dextrose in water, 657  
cefotaxime sodium; additives, injections, i.v., 33  
charcoal activated; adsorption, lack, sucrose, in vitro, 797  
chlorpheniramine maleate; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
cisplatin; solutions, UV spectrometry, 38  
diazepam; injections, i.v., in plastic and glass, 505; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
doxorubicin hydrochloride; injections, effects, temperature, 1536  
drugs; hospital pharmacy, use of lot numbers, 1545; temperature, lists, not to be refrigerated, 1541  
FreAmine II and additives, discoloration, and precipitation, 511  
glycopyrrolate; incompatibilities, additives, effects, pH, 508; incompatibilities, i.v., vehicles and additives, 508  
heparin sodium; additives, injections, pH and time, in dextrose in water and dextrose in sodium chloride, 618  
hydralazine hydrochloride; tablets, storage, counting machine, spectrometry, and colorimetry, 1539  
methyldopa; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
nitroglycerin; injections, i.v., extemporaneous, 173  
papaverine hydrochloride; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
penicillin V potassium; syringes, oral, plastic, various temperatures, 205; temperature, freezing, effects, reconstituted unit dose, 209  
pentaerythritol tetranitrate; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
phenobarbital; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
phenytoin sodium; capsules, storage, counting machine, spectrometry and colorimetry, 1539  
propantheline bromide; tablets, counting machine, spectrometry and colorimetry, 1539  
propranolol hydrochloride; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
sodium salicylate; adsorption, sucrose and activated charcoal mixtures, 797  
spironolactone; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
stannous chloride dihydrate; ions, stannous, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370  
sulfisoxazole; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
tetracycline; additives, FreAmine II, incompatibilities, 511  
tolbutamide; tablets, storage, counting machine, spectrometry and colorimetry, 1539  
**Stannous chloride dihydrate**; stability; ions, stannous, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370  
**Statistics**  
hospital pharmacy; purchasing, and inventory, 1978 survey, 650  
pharmaceutical services; hospitals, 1978, comparison, survey, 1975; 316  
**Sterility**; admixtures, injections, compounding times and contamination rates, 513  
**Steroids, corticosteroids**; education; patients, adrenalectomy, by hospital pharmacists, 1212  
Reye's syndrome; therapy, review, 767  
sarcooidosis; therapy, discussion, 351  
**Storage**  
amoxicillin trihydrate; temperature, freezing, effects, stability, reconstituted unit dose, 209  
ampicillin; temperature, freezing, effects, stability, reconstituted unit dose, 209  
diazepam; containers, plastic, decreased stability, 505  
dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539  
drugs; hospital pharmacy, use of lot numbers, 1545  
heparin sodium; additives, stability, in dextrose in water and dextrose in sodium chloride, 618  
nitroglycerin; injections, i.v., extemporaneous, stability and potency, 173  
penicillin V potassium; temperature, freezing, effects, stability, reconstituted unit dose, 209  
stannous chloride dihydrate; ions, stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370  
**Sucrose**; adsorption; charcoal activated, lack, in vitro, 797  
**Sulfamethoxazole**; combination, trimethoprim; effects, mechanism of action, pharmacokinetics, drug interactions and adverse reactions, review, 893; infections, combined therapy, granulocytic cancer patients, 178  
**Sulfapyrazole**; gout; and hyperuricemia, therapy, discussion, 497  
**Sulfisoxazole**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Surgical supplies**; administration sets; contamination, microbiological, determination, membrane filter set, 1202; effects, insulin availability, low-dose continuous injections, 330; filters, membrane, inline, effects, air flow, 749; models, flow rates, 338  
**Sustained-action medications**; theophylline; tablets, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; tablets, dosage schedules, blood levels, asthmatic children, 1698  
**Sympatholytic agents**; tolazoline; rational therapy, clonidine overdose, review, 906  
**Syringes**  
meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094  
plastics; penicillin V potassium, oral, stability, 205  
**Syrups**; meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094

**T****Tablets**

aluminum hydroxide, combination, magnesium hydroxide, simethicone; equivalency, generic, acid reactivity, in vitro, 660  
aminophylline; comparison, theophylline sustained-action tablets, effects and blood levels, patients, 613  
ascorbic acid; stability, storage, counting machine, spectrometry and colorimetry, 1539  
aspirin; stability, storage, counting machine, spectrometry and colorimetry, 1539  
chlorpheniramine maleate; stability, storage, counting machine, spectrometry, and colorimetry, 1539  
diazepam; stability, storage, counting machine, spectrometry and colorimetry, 1539  
hydralazine hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539  
magnesium hydroxide, combination, aluminum hydroxide, simethicone; equivalency, generic, acid reactivity, in vitro, 660  
methyldopa; stability, storage, counting machine, spectrometry and colorimetry, 1539  
papaverine hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539  
pentaerythritol tetranitrate; stability, storage, counting machine, spectrometry and colorimetry, 1539  
phenobarbital; stability, storage, counting machine, spectrometry and colorimetry, 1539  
propantheline bromide; stability, storage, counting machine, spectrometry and colorimetry, 1539  
propranolol hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539  
simethicone, combination, aluminum hydroxide, magnesium hydroxide; equivalency, generic, acid reactivity, in vitro, 660  
spironolactone; stability, storage, counting machine, spectrometry and colorimetry, 1539  
sulfisoxazole hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539  
theophylline; sustained-action, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; sustained-action, dosage schedules, blood levels, asthmatic children, 1698  
tolbutamide; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Temperature**  
amoxicillin trihydrate; effects, freezing, on stability, reconstituted unit dose, 209  
ampicillin; effects, freezing, on stability, reconstituted unit dose, 209  
cefotaxime sodium; stability, additives, 33  
cisplatin; stability, solutions, 38  
doxorubicin hydrochloride; injections, stability, effects, 1536  
drugs; stability, lists, not to be refrigerated, 1541  
ions; stannous, stability, stannous chloride dihydrate, comparison, commercial and extemporaneous ions, radiopharmaceutical kits, 1370  
nitroglycerin; injections, i.v., extemporaneous, effects on stability, 173  
penicillin V potassium; effects, freezing, on stability, reconstituted unit dose, 209; stability, syringes, oral, plastic, 205  
**Tests, laboratory**; thromboplastin time; effects, heparin, dosage schedules, based upon pharmacokinetics, 920  
**Tetracycline**; interactions; antacids, monitoring, programs, outpatients, 653  
**Tetracycline hydrochloride**; incompatibilities; FreAmine II, visual, 511  
**Theophylline**  
blood levels; lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059  
dosage; oral, using clearance rates following i.v. infusion, patients, 66  
education; patients, audiovisual, with and without pharmacists present, 63  
information; comparison, services, 1215  
tablets; sustained-action, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; sustained-action, dosage schedules, blood levels, asthmatic children, 1698  
**Thiopental sodium**; incompatibilities; glycopyrrolate, effects, pH, 508  
**Thioridazine**; adverse reactions; hyperpyrexia, schizophrenic patient, 674  
**Ticarcillin**  
and amikacin, gentamicin or netilmicin; toxicity, ear, leukopenic patients, 1083  
infections; combined therapy, granulocytic cancer patients, 178  
**Time studies**  
admixtures; injections, compounding time and contamination rates, 513  
hospital pharmacy; pharmacists, and supportive personnel, comparison, methods, 59  
pharmacists; decentralized, emergency, room, costs, 52  
pharmacists, hospital; workload, productivity evaluation, 201  
**Tobramycin**; drug use review; pharmacists, hospitals, 1209  
**Tobramycin sulfate**; incompatibilities; cefoxitin sodium, lack, in vitro, 33  
**Tolazoline**; rational therapy; clonidine, overdose, review, 906  
**Tolbutamide**  
adverse reactions; hyponatremia, patients, 1107  
tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Toxicity**  
amikacin and ticarcillin; ear, leukopenic patients, 1083  
aminoglycosides and cephalothin sodium; kidney, granulocytic cancer patients, 178  
amphotericin B; review, 1326  
ampicillin; diarrhea, prophylaxis, *Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*, patients, 754  
anticoagulants; monitoring, pharmacists, hospital, 214  
butorphanol tartrate; side effects, review, 1683  
catheters; plastics, thrombosis, effects, physical characteristics, 1707  
cephalothin sodium and aminoglycosides; kidney, granulocytic cancer patients, 178  
clonidine; overdose, and therapy, review, 906  
clotrimazole; review, 1326  
digitoxin; poisoning, antidotes, patients, 92  
digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968  
drugs; monitoring, computers, programs, hospitalized patients, 198; poisoning, antidotes, effects, electrolyte blood levels, patients, 1366; poisoning, pediatric, pharmacists, consultation, clinical toxicology service, 1087; skin, monitoring, hospitals, patients, 609  
estrogens; patients, peri- and postmenopausal, review, 1062  
flucytosine; review, 1326  
gentamicin and ticarcillin; ear, leukopenic patients, 1083  
griseofulvin; review, 1326  
injections; i.v., contamination, effects of membrane final-filter pore size on survival, rabbits, 1711; i.v., phlebitis, effects, inline membrane final filters, postoperative patients, 1355  
miconazole nitrate; review, 1326  
netilmicin and ticarcillin; ear, leukopenic patients, 1083  
nitrofurantoin; side effects, review, 342  
nystatin; review, 1326  
psychotherapeutic agents; extrapyramidal disorders, prophylaxis, antiparkinson agents, patients, 641  
quinidine sulfate and digoxin; blood levels, digoxin, increased, patient, 968

ticarcillin and amikacin, gentamicin or netilmicin; ear, le-  
ukopenic patients, 1083

#### Tranquilizers

diazepam; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
thioridazine; hyperpyrexia, schizophrenic patient, 674  
Trimethoprim; combination, sulfamethoxazole; effects, mechanism of action, pharmacokinetics, drug interactions and adverse reactions, review, 893; infections, combined therapy, granulocytic cancer patients, 178  
Turnover; inventory; hospital pharmacy, statistics, 1978 survey, 650

## U

Unit dose drug distribution systems, see Drug distribution systems; unit dose  
Urea; Rey's syndrome; therapy, review, 767

## V

Vehicles; heparin sodium; injections, stability, dextrose in water or sodium chloride, 618  
Vials; meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094

## W

Warfarin; patient information; hospitals, pharmacists and nurses, 219  
Warfarin sodium  
dosage; methodology, prothrombin time, patients, 1351  
and heparin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
Weight  
dosage forms; tablets, and capsules, counting machine,

effects on stability, spectrometry and colorimetry, 1539  
patients; effects, heparin injection rate, 782

#### Workload

clinical pharmacists; drug use review, hypotensive agents, family-practice clinic, 1665  
hospital pharmacy; pharmacists, and supportive personnel, comparison, methods, 59  
personnel, pharmacy; supportive, technicians, injections, i.v., comparison, systems, 1497  
pharmacists; decentralized, emergency room, costs, 52  
pharmacists, hospital; charges, drugs, based upon medication administration records, 365; computers, development of multifunctional drug file, 1197; computers, word-processing machines compared, 1529; outpatients, services, 1978 survey, university-affiliated, 1193; time studies, productivity evaluation, 201

## X

Xanthine oxidase inhibitors; allopurinol; allergies, patients, 1377

## Author Index

## A

Alexander, Bruce Book review, 1584  
Alexander, Michael R. Book review, 1584  
Alexander, Michael R. Savings achieved through selection of amino acid solutions (letter), 598  
Alexander, Michael R. see also McGee, Jackie L., 633  
Allen, Loyd V. Jr. Freezing of suspensions (letter), 1160  
Allen, Loyd V. Jr. Stability of oral liquid penicillins in unit dose containers at various temperatures, 209  
Allen, Loyd V. Jr. see also Frech, Gary, 1672  
Allinson, Russel R. Book review, 1588  
Allinson, Russel R. Comparison of plastic containers for intravenous solutions (letter), 1035  
Allinson, Russel R. Compounding times and contamination rates associated with the preparation of intravenous admixtures in three types of plastic containers, 513  
Altman, Michael see Dasta, Joseph, 613, 1028  
Alvarez, Salvador see Glickman, Richard, 342, 893, 1071, 1077, 1509  
Amadio, Peter Jr. see Vlasses, Peter H., 1046  
Ameer, Barbara Drug therapy reviews: Evaluation of butorphanol tartrate, 1683  
Amerson, Ann B. see Magera, Barbara E., 1062  
Anderson, C. W. David Savings achieved through selection of amino acid solutions (letter), 597  
Anderson, Joan M. Pharmacy internship: Patient care experience through nursing service, 791  
Anderson, Robert J. see Spiegel, Robert W., 52  
Archambault, George F. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 476  
Armistead, Sidney Preparation of cardioplegic solutions, 1361  
Arnold, Lawrence A. Effect of an antacid on gastrointestinal absorption of theophylline, 1059  
Athanasik, Narayan Visual compatibility of 30 additives with a parenteral nutrient solution, 511  
Autian, John see Czajka, Peter A., 1087  
Avis, Kenneth E. Editorial, 1489  
Ayres, James W. see Giscion, Lee G., 1179  
Ayres, James W. see also Stennett, Douglass J., 657

## B

Bair, Jan N. Surface characteristics of plastic intravenous catheters, 1707  
Bair, Jan N. see also Lipman, Arthur G., 1513  
Bair, Jan N. see also Rusho, William J., 1355  
Baker, Carol L. see Knapp, Deanne E., 1334  
Baldwin, Jeffrey N. see Grogan, Larry J., 205  
Baluch, William see Ivey, Marianne F., 57, 598  
Barger, Robert Preparation of sterile, pyrogen-free, bacteriostatic solutions of zinc sulfate and copper sulfate (letter), 1156  
Barreuther, Alan D. Book review, 1117  
Barriers, Steven L. Aminoglycoside use monitored by clinical pharmaceutical services, 1209  
Barriere, Steven L. Book review, 542  
Barriere, Steven L. Predicting aminoglycoside serum levels (letter), 28

Barriere, Steven L. see also Hales, Kelly, 773  
Bartle, W. R. Effects of neomycin on the bioavailability of spirinolactone: A single-dose study, 1701  
Baumgartner, Thomas G. Administration of hydroxyzine injection (letter), 1660  
Baumgartner, Thomas G. Pharmacy support encouraged for home health care legislation (letter), 1651  
Bean, Charles L. Definition of clinical pharmacy (letter), 744  
Bechtel, Thomas P. see Moore, Timothy D., 1107  
Bell, J. Edward see Bernick, John J., 1493  
Bender, John F. Book review, 698  
Bender, John F. Comparative auditory toxicity of aminoglycoside antibiotics in leukopenic patients, 1083  
Berardi, Rosemary R. Book review, 979  
Berardi, Rosemary R. see also Joy, Reuben T., 618  
Berman, Alex Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 463  
Bernick, John J. Adventitious contamination of intravenous admixtures during sterility testing, 1493  
Bivins, Brack A. see Rapp, Robert P., 1711  
Bivins, Brack A. see also Rusmin, Simon, 749  
Black, Harold J. see Hanson, Don B., 1197  
Blackstone, Marilyn Potential for error with Cornwall-type fluid dispensing devices (letter), 27  
Blissenbach, Thomas J. see Majkowiak, Kenneth E., 1470  
Bloomfield, J. C. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 483  
Blough, Sue S. see Greenlaw, Cal W., 1080  
Boersma, Ronald B. see Fredrick, David S., 778  
Bootman, J. Lyle Cost of individualizing aminoglycoside dosage regimens, 368  
Bootman, J. Lyle Data analysis in study of physicians' attitudes (letter), 161  
Bosso, John A. see Lipman, Arthur G., 1513  
Bowman, John D. see Armistead, Sidney, 1361  
Boyer, Bill see Athanasik, Narayan, 511  
Braine, Hayden G. see Summerfield, Marc, 1470  
Brands, Allen J. The patient's pharmacist, 311  
Branson, Joanne B. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 470  
Briggs, Jerry Glaucoma screening program at Midyear detects two cases (letter), 1303  
Brodie, Donald C. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 464  
Brodie, Donald C. see also Hlynka, John N., 1347  
Brown, David J. Evaluation of clinical pharmacist consultations in a family practice office, 912  
Brown, Don G. see Bernick, John J., 1493  
Brown, Murray A. see Miller, Donald R., 1351  
Brown, Thomas R. Reference aids for developing policies and procedures for intravenous admixture services, 517  
Browne, Thomas R. Intravenous administration of phenytoin (letter), 296  
Bryan, Candace Kendle Bretylium tosylate: A review, 1189  
Burack, Herbert Professional degrees: What's in a name? (letter), 596  
Burckart, Gilbert J. Therapy of Rey's syndrome (letter), 1657  
Burckart, Gilbert J. see also Mutchie, Kelly D., 767

Burke, Wayne S. Effect of quinidine on serum digoxin concentrations, 988  
Burke, Wayne S. Management of quinidine-induced elevations of serum digoxin (letter), 1480  
Burleson, Ken A. see Hester, Pat, 1316  
Burleson, Ken W. see Hester, Pat, 1316  
Busto, Usua Drug monitoring: The University of Chile Clinical Hospital experience (letter), 596  
Buth, Jonathan A. Clinical pharmacokinetic articles (letter), 27

## C

Cady, William J. Book review, 109  
Cady, William J. Use of cholestyramine resin in the treatment of digoxin toxicity, 92  
Campagna, Keith D. see Sula, Joseph A., 50  
Campbell, James see Cady, William J., 92  
Carlin, Herbert S. see Romankiewicz, John A., 1541  
Carlson, Carla News, 563, 852, 854, 1272  
Chan, Nora L. Book review, 109  
Chatterji, Dulal C. see Greene, Raymond F., 38  
Chenella, Frank C. Continuous versus intermittent intravenous heparin therapy (letter), 1307  
Chenella, Frank C. Improved method for estimating initial heparin infusion rates, 782  
Childress, K. Jan see Stallings, Sylvia B., 68  
Cipolle, Robert J. see Rector, Tom S., 1561  
Cluxton, Robert J. Jr. Book review, 834  
Cluxton, Robert J. Jr. Comparison of five information services as sources for bioavailability data, 1215  
Coarse, James F. Objective-focused approach for appraising the performance of institutional pharmacists, 1676  
Coates, P. E. see Bartle, W. R., 1701  
Cohen, Edward M. see O'Brien, Matthew J., 33  
Cohen, Hedy see Thomas, Russel R., 888  
Cohen, Michael R. see Thomas, Russel R., 888  
Cohen, Stanley N. see Tatro, David S., 198  
Cohn, Victor News, 408  
Collins, G. Edward see Armistead, Sidney, 1361  
Conner, Christopher S. Clonidine overdose: A review, 906  
Conner, Christopher S. Errors in the de Haen Drugs-in-Use Drug Information System (letter), 448  
Conte, John E. Jr. see Barriere, Steven L., 1209  
Conti, Vincent R. see Armistead, Sidney, 1361  
Cooney, David O. Sucrose as a sweetener for activated charcoal, 797  
Cross, Martha L. see McGowan, John E. Jr., 376  
Cullen, Stanley I. see Stewart, Ronald B., 609  
Cutler, Bruce S. see Welch, Gary W., 446  
Czajka, Peter A. Clinical toxicology consultation by pharmacists, 1087

## D

Damin, LeeAnne see Hoffman, Dennis M., 1536  
Darby, Monica H. see Bryan, Candace Kendle, 1189  
Darr, Marilyn S. Theophylline education: Development and evaluation of teaching methods, 63  
Dasta, Joseph Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease, 613  
Dasta, Joseph F. Emesis in the treatment of paraquat poisoning (letter), 305



- Dasta, Joseph F. Estimation of theophylline half-life from theophylline clearance (letter), 1028  
 Deamer, Robert see Athanikar, Narayan, 511  
 Deffenbaugh, Elmer Clarification on legal status of some antihistamine products (letter), 27  
 DeLuca, Alfred R. PPI requirements (letter), 743  
 DeLuca, Patrick P. Binding of drugs to inline filters (letter), 151  
 DeLuca, Patrick P. see also Gatlin, Larry, 1357  
 DeLuca, Patrick P. see also Rapp, Robert P., 1711  
 DeLuca, Patrick P. see also Rusin, Simon, 749  
 Dembicki, Eugene L. Phencyclidine intoxication (letter), 305  
 Derewicz, Henry J. see Hollander, David H., 1163  
 Derewicz, Henry J. see also Roffe, Bruce D., 211  
 Dick, Robert W. see Hanson, Don B., 1197  
 Digerness, Stanley B. see Armistead, Sidney, 1361  
 DiPiro, Joseph T. Work sampling to evaluate staff pharmacist productivity, 201  
 Dirks, Isabella Charging for hospital pharmaceutical services: Combined product-service per diem fees, 363  
 Dombrower, Paul Intravenous erythromycin dosages (letter), 1654  
 Domecq, Catalina see Busto, Usoa, 596  
 Douglas, Herschel L. see Hawkins, David W., 1321  
 DuBe, James E. see Durr, Marilyn S., 63  
 Duffy, Sister M. Gonzales Realizing the promise of hospital pharmacy, 938  
 Dugas, James E. see Kubica, Anthony J., 194  
 Dwork, Lawrence J. see Thomas, Russel R., 888

## E

- Eckel, Fred M. Book review, 824  
 Edwards, S. Albert Book review, 1114  
 Eichelberger, Bernadette M. News, 122, 258, 563, 992, 1728  
 Ekins, Brent R. Book review, 824  
 Ellenor, Gary L. Book review, 1416  
 El-Mallakh, Rif Incompatibilities with cimetidine hydrochloride injection (letter), 1024  
 Eschbach, Robert C. see Hawkins, David W., 1321  
 Evans, Donna M. Pharmacy practice in an operating room complex, 1342  
 Evans, William E. Book review, 1719  
 Evans, Ronald P. Book review, 1583  
 Evans, Ronald P. Drug therapy reviews: Antirheumatic agents, 622  
 Ewing, Gerald H. see Giscion, Lee G., 1179

## F

- Fanburg, Barry L. Drug therapy reviews: Treatment of sarcoidosis, 351  
 Faraci, Philip A. see Weiner, Bruce, 444  
 Feezor, Mike see Ziser, Mark, 1090  
 Feldman, Marvin J. Determining the date of manufacture of drug products from lot numbers, 1545  
 Fiedler, Fred P. see Hawkins, David W., 1321  
 Fink, Joseph L. III Patient package inserts and the pharmacist's responsibility, 226  
 Fischella, Robert P. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 473  
 Fish, Kenneth H. Jr. Charging for hospital pharmaceutical services: Computerized system using a markup and a dose fee, 360  
 Fisher, M. M. see Bartle, W. R., 1701  
 Floyd, Ronald A. Book review, 1583  
 Floyd, Ronald A. Estimation of theophylline half-life from theophylline clearance (letter), 1025  
 Floyd, Ronald A. see also Chenella, Frank C., 782  
 Forer, Morris Home drug use by fixed-income patients (letter), 28  
 Fortner, Clarence L. see Bender, John F., 1083  
 Fortner, Clarence L. see also Grove, William R., 452  
 Fotis, Michael see Tribble, Dennis A., 739  
 Fox, Samuel M. Haloperidol in the treatment of phenocyclidine intoxication (letter), 448  
 Francke, Donald E. Editorial, 455  
 Francke, H. Edward Appreciation expressed for Francke tribute (letter), 1659  
 Francke, Jon E. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 463  
 Francke, Markay M. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 462  
 Fraser, Donald G. Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of cefamandole and cefoxitin, 1503  
 Frattigro, Carl C. see Palmer, Marcia A., 596, 1025  
 Frazier, Dorothy L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 470

- Frech, Gary Sodium acetate as a preservative in protein hydrolysate solutions, 1672  
 Fredrick, David S. Lidocaine infusions: Effect of duration and method of discontinuation on recurrence of arrhythmias and pharmacokinetic variables, 778  
 Fritz, William L. see Paxinos, James, 1497  
 Frost, John K. see Hollander, David H., 1163  
 Fuentes, Robert J. Formulary decisions concerning cephalosporins (letter), 296  
 Fujitaki, Wayne H. see Tanaka, Gerald J., 1044  
 Fung, Ho-Leung see McNiff, Barbara Lenard, 173

## G

- Gabrielson, R. M. Rational use of methenamine mandelate (letter), 1658  
 Gallilelli, Joseph F. see Greene, Raymond F., 38  
 Gallina, Joseph N. see Mahoney, Charles D., 1533  
 Gallo, Ulisse Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 484  
 Garb, Solomon Tobacco addiction among health professionals (letter), 1163  
 Gatlin, Larry Determining osmolalities: A practical approach for multicomponent intravenous and parenteral nutrient solutions, 1357  
 Geiger, Gail S. see Greenlaw, Cal W., 28  
 Gennaro, Alfonso R. see Vlases, Peter H., 1046  
 Gill, Gary W. see Roffe, Bruce D., 211  
 Gill, Mark A. Altered gentamicin distribution in ascitic patients, 1704  
 Gill, Mark A. Book review, 1588  
 Gill, Mark A. see also Chenella, Frank C., 782  
 Giscion, Lee G. Pharmacokinetics of orally administered dyphylline, 1179  
 Gleckman, Richard Drug therapy reviews: Methenamine mandelate and methenamine hippurate, 1509  
 Gleckman, Richard Drug therapy reviews: Nalidixic acid, 1071  
 Gleckman, Richard Drug therapy reviews: Nitrofurantoin, 342  
 Gleckman, Richard Drug therapy reviews: Oxolinic acid, 1077  
 Gleckman, Richard A. Rational use of methenamine mandelate (letter), 1658  
 Gleckman, Richard Drug therapy reviews: Trimethoprim-sulfamethoxazole, 893  
 Gleckman, Richard see also Rybak, Michael J., 738  
 Godley, Leo F. Honorary members convey gratitude to ASHP (letter), 446  
 Godley, Leo F. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 469  
 Goldstein, Ellie J. C. see Ma, Mary Y., 1055  
 Goldstein, Martin S. Use of the metric system and Celsius scale in U.S. medical and pharmaceutical journals (letter), 1166  
 Good, James W. see Honda, Dennis H., 742  
 Goodhart, Frank W. see Spivey, R. J., 660  
 Gordon, Fred S. see Levine, Howard G., 788  
 Gotz, Vincent Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation, 754  
 Gotz, Vincent P. see also Romankiewicz, John A., 1541  
 Gousse, Gregory C. see DiPiro, Joseph T., 201  
 Gousse, William L. Book review, 838  
 Gouveia, William A. An ASHP SIG on computerized pharmacy systems? (letter), 887  
 Grambau, Geoffrey see Slotfield, Marilyn L., 66  
 Graziani, Leonard J. see Rosenberry, Kathleen R., 736  
 Greenberg, Robert B. The Kennedy version of the Drug Regulation Reform Act, 1230  
 Greene, Raymond F. Stability of cisplatin in aqueous solution, 38  
 Greenlaw, Cal W. Aminoglycoside serum assays restricted through a pharmacy program, 1080  
 Greenlaw, Cal W. Drug interaction between co-trimoxazole and warfarin (letter), 1155  
 Greenlaw, Cal W. Pharmacist as team leader for total parenteral nutrition therapy, 648  
 Greenlaw, Cal W. Standardized heparin dosage schedule using pharmacokinetic principles, 920  
 Greenlaw, Cal W. TPN formulations (letter), 28  
 Greifenhagen, Robert Pharmacy system for screening ambulatory patients, 916  
 Grogan, Larry J. Stability of penicillin V potassium in unit dose oral syringes, 205  
 Grossano, Dennis D. see Hoffman, Dennis M., 1536  
 Groth, Paul E. Modifications in the Paul de Haen Drug Information System (letter), 745  
 Grove, William R. Errors in the de Haen Drugs-in-Use Drug Information System (letter), 452  
 Grove, William R. see also Bender, John F., 1083  
 Grussing, Paul G. see Sula, Joseph A., 50  
 Guenther, Ann M. see Evans, Donna M., 1342  
 Gunter, James M. see Gupta, V. Das, 1094  
 Gupta, V. Das see Gupta, V. Das, 1539  
 Gupta, V. Das Simple techniques to detect adulteration of meperidine hydrochloride products, 1094

- Gupta, V. Das Stability of some oral solid drug products when stored in a counting machine, 1539

## H

- Haddad, Abraham see Traub, Scott L., 296  
 Haggerty, Jeanette A. Book review, 1114  
 Hagman, Donald see Ingallinera, Thomas S., 508  
 Hahn, Davis M. see Bender, John F., 1083  
 Hak, Lawrence J. Protein requirements in TPN patients (letter), 1036  
 Hales, Kelly Polyvalent pneumococcal vaccines: A review, 773  
 Ha'ler, Jerome S. Therapy of Reye's syndrome (letter), 1654  
 Hammel, Richard J. see Bootman, J. Lyle, 161  
 Hammel, Richard J. see also Paxinos, James, 1497  
 Hanan, Zachary I. see Levine, Howard G., 788  
 Hanson, Don B. Development of a multi-functional drug file for hospital pharmacy computer applications, 1197  
 Hansten, Philip D. see Jinks, Martin J., 923  
 Harbison, Harry see Athanikar, Narayan, 511  
 Harrison, Willard L. see Klapp, Deborah, 1205  
 Haug, Marcus T. III see Greenlaw, Cal W., 28  
 Haugen, Roger K. see Greenlaw, Cal W., 1080  
 Haughey, David B. Allolpurinol sensitivity: Report of two cases, 1377  
 Hawkins, David W. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients, 1321  
 Hays, Dennis P. see Welch, Gary W., 446  
 Helling, Dennis K. Comparison of computer-assisted medical record audit with other drug use review methods, 1665  
 Helling, Dennis K. Effect of direct clinical pharmaceutical services on patients' perceptions of health care quality, 325  
 Helling, Dennis K. see also Brown, David J., 912  
 Henderson, William M. see Arnold, Lawrence A., 1059  
 Henri, Lise Intravenous administration of phenytoin (letter), 295  
 Henrietta, Geoffrey C. see Greenlaw, Cal W., 920  
 Henry, R. Scott see Athanikar, Narayan, 511  
 Hepler, Charles D. see Helling, Dennis K., 325, 1665  
 Herman, Ronald A. see Helling, Dennis K., 1665  
 Herrick, James D. see Miller, Robert F., 371  
 Herstein, Michel Francke Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 462  
 Hester, Pat Comparison of magnesium-aluminum liquid antacids (letter), 1316  
 Hibbard, F. James, see Lipman, Arthur G., 1513  
 Hildebrandt, William K. Concomitant use of clonazepam and valproic acid in treatment of epileptic seizures (letter), 22  
 Hiranaka, Paul K. see Greene, Raymond F., 38  
 Hirschman, Joseph L. see Jinks, Martin J., 923  
 Hlyzka, John N. Developing drug-use profiles from drug-charge records, 1347  
 Ho, Norman F. H. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 468  
 Ho, Norman F. H. see also Joy, Reuben T., 618  
 Hockensmith, Joel W. see Vlases, Peter H., 1046  
 Hoffman, Dennis M. Stability of refrigerated and frozen solutions of doxorubicin hydrochloride, 1536  
 Hollander, David H. Preservative-free heparinized bottles suitable for cytogenetics as well as for cytopathology (letter), 1163  
 Honda, Dennis H. Preprinted physician's order form for intravenous cisplatin therapy (letter), 742  
 Hopeff, Alan W. Empiric therapy of febrile granulocytopenic patients, 178  
 Hopkins, Leigh Author affiliation clarified (letter), 1307  
 Hopkins, Leigh E. see also Lee, Mary, 1478  
 Horn, John R. Response rates and direct reprint requests, 1219  
 Hunt, Susan N. Book review, 828  
 Hunter, Robert H. see Cluxton, Robert J. Jr., 1215  
 Hussain, Anwar see Gatlin, Larry, 1357  
 Hutchinson, Richard A. see Meinhold, Jane M., 1520  
 Hutchinson, Richard A. see also Nelson, Arthur A. Jr., 164  
 Hutchinson, Richard A. see also Sula, Joseph A., 50  
 Hyneck, Martha L. see Joy, Reuben T., 618  
 Hynaiman, Clifford E. Organizational initiatives for hospital pharmacy in the 1980s, 941

## I

- Ignoffo, Robert J. Correction of errors in *Applied Therapeutics for Clinical Pharmacists* (letter), 1044  
 Imhoff, Thomas see Haughey, David D., 1377

**Ingallinera, Thomas S.** Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives, 508

**Ivey, Marianne** Administration of hydroxyzine injection (letter), 1660

**Ivey, Marianne** Savings achieved through selection of amino acid solutions (letter), 598

**Ivey, Marianne F.** Savings achieved through use of a less concentrated amino acid solution, 57

## J

**Jackowitz, Arthur I.** Thioridazine-induced hyperpyrexia—a case report, 674

**Jakobs, Eleanor** see Scalley, Robert D., 219

**Jansen, James R.** see Honda, Dennis H., 742

**Jeffrey, Louis P.** Salary survey of hospital pharmacy residency programs (letter), 1300

**Jeffrey, Louis P.** see also Mahoney, Charles D., 1533

**Jensen, Bradford K.** see Grogan, Larry J., 205

**Jinks, Martin J.** Drug interaction exposures in a Medicaid ambulatory population, 923

**Johnson, Cary E.** see Slotfeldt, Marilyn L., 66, 453, 745

**Johnson, Todd A.** see Kellenberger, Thomas A., 230

**Jones, Mark E.** see Brown, David J., 912

**Jones, Mark E.** see also Helling, Dennis K., 325

**Joubert, Dennis W.** see Gleckman, Richard, 342, 893, 1071, 1077, 1509

**Joy, Reuben T.** Effect of pH on the stability of heparin in 5% dextrose solutions, 618

**Juhl, Randy P.** Comparison of kaolin-pectin and activated charcoal for inhibition of aspirin absorption, 1097

**Juluson, Dick.** see Mutchie, Kelly D., 785

**Jump, Walter G.** Estimated versus measured serum digoxin levels (letter), 166

**Jurgens, Raymond Jr.** see Athanikar, Narayan, 511

## K

**Kapadia, A. J.** see Ingallinera, Thomas S., 508

**Katcher, Brian S.** Book review, 1118

**Katz, Edward** Formulary decisions concerning cephalosporins (letter), 300

**Katz, Robert E.** see Uliana, Mark, 1024

**Katz, Robert M.** Society membership and educational program plans for hospital pharmacy supportive personnel (letter), 161

**Kaul, Alan F.** see Feldman, Marvin J., 1545

**Kearney, Elizabeth** see Scalley, Robert D., 219

**Keith, Thomas D.** see Evans, Donna M., 1342

**Kellenberger, Thomas A.** Essential fatty acid deficiency: A consequence of fat-free total parenteral nutrition, 230

**Kelly, H. William** Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets, 1698

**Kelly, William N.** Book review, 532

**Kendall, James D.** Determining chronic oral dosage regimens for theophylline (letter), 744

**Kent, Susan** see Plein, Jay B., 44

**Kepler, Judith A.** Book review, 1422

**Kerkhof, Kent** Comparison of plastic containers for intravenous solutions (letter), 1028

**Kern, Jack W.** see Chenella, Frank C., 782

**Kern, Jack W.** see also Gill, Mark A., 1704

**Kessler, Wayne V.** see McBride, Martin H. D., 1370

**Keys, Philip W.** Drug interaction between co-trimoxazole and warfarin (letter), 1155

**Kimberlin, Carole L.** see Darr, Marilyn S., 63

**King, Charles M. Jr.** Book review, 1247

**Kirk, Kenneth W.** Book review, 1420

**Kirschenbaum, Harold L.** Stability of procainamide in 0.9% sodium chloride or dextrose 5% in water (letter), 1464

**Kirschenbaum, Harold** see Sesin, George P., 1565

**Kitrenos, Jack G.** Effectiveness of i.v. controllers (letter), 1306

**Klacsman, Karen T.** see Hollander, David H., 1163

**Klapp, Deborah** Evaluation of albumin use by medical audit, 1205

**Klink, Paul R.** Production of carbon dioxide gas after reconstitution of cefamandol nafate (letter), 597

**Kloze, Oscar** see Ingallinera, Thomas S., 508

**Kluza, Ronald B.** Book review, 823

**Knapp, David A.** see Knapp, Deanne E., 1334

**Knapp, Deanne A.** see also Knapp, Dee A., 1553

**Knapp, Deanne E.** Relationship of inappropriate drug prescribing to increased length of hospital stay, 1334

**Knapp, Deanne E.** see also Knapp, Dee A. (same person)

**Knapp, Dee A.** Developing criteria for drug prescribing review—A SIG project? (letter), 1465

**Knapp, Dee A.** Strategy for increasing the demand for clinical pharmacists, 1553

**Knapp, Dee A.** see also Knapp, Deanne E. (same person)

**Koda, Robert T.** Model for evaluating flow properties of intravenous administration sets, 338

**Kohlberg, Joshua** Appreciation expressed for Francke tribute (letter), 1659

**Korberly, Barbara H.** see Rosenberry, Kathleen R., 736

**Korman, Nancy** see Ignoffo, Robert J., 1044

**Kotzan, Jeffrey A.** see Segall, L. Elliott, 59

**Krier, Thomas** Emesis in the treatment of paraquat poisoning (letter), 305

**Kubica, Anthony J.** Screening and selecting candidates for a hospital pharmacy residency program, 194

**Kubica, Anthony J.** see also Coarse, James F., 1676

**Kubica, Anthony J.** see also DiPiro, Joseph T., 201

**Kuehne, Carolyn** Sodium chloride residue provides potential for drug incompatibilities (letter), 881

**Kulkarni, Prakash** see Gatlin, Larry, 1357

## L

**Lambert, Ivan** see Katz, Robert M., 161

**Lambert, Ivan** see also Traub, Scott L., 296

**Lamy, Peter P.** see Grove, William R., 452

**Land, Nancy** Book review, 1247

**Lang, Bela** Appreciation expressed for Francke tribute (letter), 1659

**Laning, Laurence J.** Method for evaluating drug information systems, 793

**Lanse, Steven** see Haughey, David B., 1377

**Latiolais, Clifton J.** Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 465

**Latiolais, Clifton J.** see also Allinson, Russel R., 513, 1035

**Latiolais, Clifton J.** see also Whalen, Forrest J., 330

**Lau, Steven C.** see Koda, Robert T., 338

**Lazarus, Herman L.** see Evans, Donna M., 1342

**Leach, Donald B.** Book review, 1118

**LeCain, William K.** see Whalen, Forrest J., 330

**LeClerc, Maurice** Appreciation expressed for Francke tribute (letter), 1660

**Lee, Herbert** Book review, 1594

**Lee, Mary** Management of quinidine-induced elevations of serum digoxin (letter), 1478

**Leonard, Michael S.** see Laning, Laurence J., 793

**Lesko, Lawrence J.** see Kirschenbaum, Harold L., 1464

**Letcher, Kenneth I.** Word-processing equipment for hospital pharmacy applications, 1529

**Levine, Howard G.** Pharmacist involvement in a defer-oxamine education program for patients with Cooley's anemia, 788

**Levinson, R. Saul** see Frech, Gary, 1672

**Levy, Gerhard** see Slattery, John T., 440

**Lewis, Benjamin P. Jr.** Potential confusion resulting from trade name similarities (letter), 1477

**Likes, Keith E.** Book review, 976

**Lilja, John** Drug product selection by formulary committees in Sweden (letter), 1042

**Lim, John C.** Technique for microbiological testing of in-use intravenous solutions and administration sets, 1202

**Lipman, Arthur G.** Decentralization of pharmaceutical services without satellite pharmacies, 1513

**Lo, Patrick** see Allen, Loyd V. Jr., 209, 1160

**Lott, Rex S.** Book reviews, 546, 550

**Louman, F. J. A.** see Bartle, W. R., 1701

**Love, Lillian J.** see Bender, John F., 1083

## M

**Ma, Mary Y.** Effect of control programs on cefazolin prescribing in a teaching hospital, 1055

**MacKay, Mark W.** see Mutchie, Kelly D., 785

**Magara, Barbara E.** Estrogen therapy of perimenopausal and postmenopausal patients, 1062

**Mahoney, Charles D.** Pharmacy technician specialist: A career opportunity, 1533

**Mahoney, Charles D.** see also Jeffrey, Louis P., 1300

**Majkowaki, Kenneth E.** "Mini" in-service education programs for nurses (letter), 1470

**Makoid, Michael C.** see Grogan, Larry J., 205

**Mangini, Richard J.** Drug therapy reviews: Pathogenesis and clinical management of hyperuricemia and gout, 497

**Marsh, Christie** see Mutchie, Kelly D., 785

**Mattea, Edward J.** Sterility of prefilled syringes for thermal dilution cardiac output measurements (letter), 1156

**Matthews, Samuel J.** see Gleckman, Richard, 1071, 1077, 1509

**Matzke, Gary R.** see Burkle, Wayne S., 968, 1480

**May, Franklin E.** see Stewart, Ronald B., 609

**Maynard, Susan M.** see Stallings, Sylvia B., 68

**McBride, Martin H. D.** Deterioration of stannous ion in radiopharmaceutical kits during storage, 1370

**McDonald, Donald E.** see Tribble, Dennis A., 739

**McGee, Jackie L.** Phenothiazine analgesia—fact or fantasy?, 633

**McGehee, William G.** see Chenella, Frank C., 782

**McGowan, John E. Jr.** Reviewing initial choice of antimicrobial therapy—problems for the individual hospital, 376

**McKeehan, C. Wayne** see Klink, Paul R., 597

**McKenney, James M.** Effect of advanced pharmaceutical services on the incidence of adverse drug reactions, 1691

**McLean, J. R.** Radiochemical purity of Tc 99m human serum albumin (letter), 1039

**McManus, Janice** see Romankiewicz, John A., 1541

**McNiff, Barbara Lenard** Potency and stability of extemporaneous nitroglycerin, 173

**McNiff, Edward F.** see McNiff, Barbara Lenard, 173

**Meade, Richard H. III** Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of erythromycin and its derivatives, 1185

**Meade, Richard H. III** Drug therapy reviews: Clinical pharmacology and therapeutic use of antimycotic drugs, 1326

**Meade, Richard H. III** Intravenous erythromycin dosages (letter), 1654

**Meinhold, Jane M.** Audit of anticoagulant therapy of pulmonary embolus, deep vein thrombosis and thrombophlebitis, 214

**Meinhold, Jane M.** Changes in drug information inquiries following implementation of clinical pharmaceutical services, 1520

**Meinhold, Jane M.** see also Nelson, Arthur A. Jr., 164

**Meltzer, Harvey J.** Charging for hospital pharmaceutical services: Daily professional fee for each drug entity dispensed (letter), 881

**Mendes, Robert W.** see Kirschenbaum, Harold L., 1464

**Mett, Christopher** see Athanikar, Narayan, 511

**Meyer, Richard D.** see Ma, Mary Y., 1055

**Milius, Peter** see Cohn, Victor, 408

**Miller, Donald R.** Predicting warfarin maintenance dosage based on initial response, 1351

**Miller, Robert F.** Modernizing an ambulatory care pharmacy in a large multi-clinic institution, 371

**Miller, Russell R.** Book review, 1116

**Miller, William A.** see Meinhold, Jane M., 214

**Minor, David R.** see Honda, Dennis H., 742

**Mirtallo, Jay M.** Book review, 1586

**Mirtallo, Jay M.** see also Dasta, Joseph, 613, 1028

**Mitchell, Gary W.** Documenting drug-drug interactions in ambulatory patients, 653

**Moore, Robert C.** Investigational drug information is available to the pharmacist (letter), 1480

**Moore, Terrence N.** see Tatro, David S., 198

**Moore, Timothy D.** Administrative approach to disaster preparedness in the pharmacy, 1337

**Moore, Timothy D.** Developing reimbursable clinical pharmacy programs: Pharmacokinetic dosing service, 1523

**Moore, Timothy D.** Hyponatremia secondary to tolbutamide and chlorothiazide, 1107

**Moore, Timothy D.** see also Kuehne, Carolyn, 881

**Morris, Marilyn E.** see Parker, William A., 505, 1103

**Moss, Jeffrey** see Gotz, Vincent, 754

**Mueller, William** see Ivey, Marianne F., 57, 598

**Mullens, Patricia Moynahan** see Laning, Lawrence J., 793

**Murphy, John E.** Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms, 641

**Murphy John E.** Potential for underdosing of oral liquid medications packaged in unit dose containers (letter), 295

**Murphy, Shirley** see Kelly, H. William, 1698

**Murray, Henry W.** see Gotz, Vincent, 754

**Mutchie, Kelly D.** Book review, 1588

**Mutchie, Kelly D.** Drug therapy of Reye's syndrome, 767

**Mutchie, Kelly D.** Pharmacist monitoring of parenteral nutrition: Clinical and cost effectiveness, 785

## N

**Nagai, Noboru** Appreciation expressed for Francke tribute (letter), 1660

**Nappi, Jean M.** Calculations for dopamine, dobutamine and nitroprusside dosages (letter), 881

**Naranjo, Claudio A.** see Busto, Ueno, 596

**Nelson, Arthur A. Jr.** Data analysis in study of physicians' attitudes (letter), 164

## Index

Nelson, Arthur A. Jr. see also Meinhold, Jane M., 1520  
 Newton, David W. Book review, 823  
 Nichols, Ned B. see Mitchell, Gary W., 653  
 Nold, Edward G. Book review, 1594  
 Nold, Edward G. see also Moore, Timothy D., 1523  
 Nold, Edward G. see also Pathak, Dev S., 1527, 1548  
 Nold, Edward G. see also Schad, Randy, 1212  
 Noori, D. S. Differences in professional degrees (letter), 1163  
 Northern, Robert E. Book review, 546  
 Northern, Robert E. see also Brown, Thomas R., 517

## O

O'Brien, Matthew J. Cefoxitin sodium compatibility with intravenous infusions and additives, 33  
 Oddis, Joseph A. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 475  
 Oddis, Joseph A. Report of Executive Vice President, 944  
 Ohtaki, Takeo Appreciation expressed for Francke tribute (letter), 1660  
 Oke, Tommy Olawuyi Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 478  
 Oliver, Joel A. see Roberts, Raymond W., 1308  
 Oslet, J. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 485  
 Otterman, Glen E. Jr. Incompatibility between carbenicillin injection and promethazine injection (letter), 1156

## P

Pakes, Gary E. Phenelzine-cola headache (letter), 736  
 Palmer, Marcia A. Clarification of "explosive-like" reaction occurring when reconstituted cefamandol nafate was stored in syringes (letter), 1025  
 Palmer, Marcia A. Production of carbon dioxide gas after reconstitution of cefamandol nafate (letter), 596  
 Pang, Fred J. see Dirks, Isabella, 363  
 Parker, Paul F. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 469  
 Parker, William A. Incompatibility of diazepam injection in plastic intravenous bags, 505  
 Parker, William A. Oral contraceptive-induced ischemic bowel disease, 1103  
 Paruta, Anthony N. see Mattee, Edward J., 1156  
 Pathak, Dev S. Cost-effectiveness of clinical pharmaceutical services: A follow-up report, 1527  
 Pathak, Dev S. Developing reimbursable clinical pharmacy programs: A goal-oriented approach, 1548  
 Paxinos, James Contamination rates and costs associated with the use of four intermittent intravenous infusion systems, 1497  
 Pearlman, Jeffrey J. see Greifenhagen, Robert, 916  
 Perrin, John H. Freezing of suspensions (letter), 1157  
 Perry, Paul J. Book review, 110  
 Peterson, Charles D. Electrolyte depletion following emergency stomach evacuation, 1366  
 Petersen, Robert V. see Bair, Jan N., 1707  
 Phillips, George L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 467  
 Pierino, Donna A. see Letcher, Kenneth I., 1529  
 Pierpaoli, Paul G. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 477  
 Pietrusko, Robert G. Drug therapy reviews: Pharmacotherapy of diarrhea, 757  
 Pietrusko, Robert G. Tetracycline and travelers' diarrhea (letter), 1312  
 Placko, John Turkey flavoring for TPN solutions (letter), 1651  
 Platek, Thomas E. Book review, 1420  
 Plein, Elmer M. see Plein, Joy B., 44  
 Plein, Joy B. Drug therapy update for the long-term-care nurse—assessment of need and evaluation of method, 44  
 Portnoff, Joel B. see O'Brien, Matthew J., 33  
 Provost, George P. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 472

## Q

Quinn, Suzanne L. see Murphy, John E., 295

## R

Raasch, Ralph H. Effects of dextran 70 on factor VIII activity, 89  
 Raebel, Marsha A. see Waller, Elaine S., 806  
 Ramirez-Lassepas, Manuel, see Rector, Tom S., 1561  
 Rapp, Robert P. Sepsis in rabbits following administration of contaminated infusions through filters of various pore sizes, 1711  
 Rapp, Robert P. see also Ruisin, Simon, 749  
 Ray, Max D. Editorial, 308  
 Reale, Elaine Obstacryk see Meinhold, Jane M., 214  
 Rector, Tom S. Characteristics of heparin-associated thrombocytopenia, 1561  
 Reed, Ronald C. see Cluxton, Robert J. Jr., 1215  
 Rehder, Terry L. see Cady, William J., 92  
 Reinders, Thomas P. Pharmacist management of anticoagulant therapy in ambulant patients, 645  
 Reith, Helmut German phenytoin formulation compatible with intravenous fluids (letter), 1317  
 Rhomberg, Mary A. News, 1728  
 Riddiough, Michael A. ASHP, politics and reimbursement (letter), 154  
 Riddiough, Michael A. Ensuring the distribution of PPIs to persons being discharged from hospitals (letter), 1651  
 Rindone, James F. Tetracycline and travelers' diarrhea (letter), 1312  
 Roach, Mark see Cooney, David O., 797  
 Roberts, Raymond W. Alternative to counter-detailing (letter), 1308  
 Rodowas, Christopher A. Jr. Clinical definitions and training costs (letter), 593  
 Rodowas, Christopher A. Jr. The Donald E. Francke tribute (letter), 744  
 Roffe, Bruce D. Heparinized bottles for the collection of body cavity fluids in cytopathology, 211  
 Romankiewicz, John A. Medications not to be refrigerated, 1541  
 Romankiewicz, John A. see also Gotz, Vincent, 754  
 Rosenberg, Jack M. Errors in the de Haen Drugs-in-Use Drug Information System (letter), 452  
 Rosenberry, Kathleen R. Combination of clonazepam and sodium valproate in the treatment of refractory epileptic seizures in 12 children (letter), 736  
 Rowland, Clayton see Bootman, J. Lyle, 368  
 Rucker, T. Donald Relative drug safety and efficacy: Any help for the practitioner?, 1099  
 Ruiz, Ines see Busto, Uscia, 596  
 Rusko, William J. Effect of filtration on complications of postoperative intravenous therapy, 1355  
 Ruisin, Simon Conditions permitting air flow through an air-venting inline filter, 749  
 Russo, John Jr. see Lipman, Arthur G., 1513  
 Rybak, Michael J. Incorrect or unsubstantiated indications listed for selected antimicrobials in the Physicians' Desk Reference (letter), 738

## S

Salter, Fred J. see Ameer, Barbara, 1683  
 Samuelson, Duane see Otterman, Glen E. Jr., 1156  
 Sawyer, William T. see Stallings, Sylvia B., 68  
 Scalliey, Robert D. Interdisciplinary inpatient warfarin education program, 219  
 Schad, Randy F. Hydroxyzine analgesia—fact or fantasy? (letter), 1317  
 Schad, Randy Reimbursable pharmacy teaching program for adrenalectomy patients, 1212  
 Schentag, Jerome J. see Haughey, David B., 1377  
 Schilling, Karl Book review, 1117  
 Schimpff, Stephen C. see Bender, John F., 1083  
 Schneider, Philip J. see Moore, Timothy D., 1523  
 Schneider, Philip J. see also Schad, Randy, 1212  
 Schneiweiss, Fred Interpretation of research idioms (letter), 1303  
 Schumacher, Gerald E. Using pharmacokinetics in drug therapy, IV: Considerations in applying pharmacokinetic and pharmacodynamic estimates to antihypertensive dosage regimens, 802  
 Schumacher, Gerald E. Using pharmacokinetics in drug therapy, V: Contributions to developing dosage regimens for antihypertensive drugs, 1222  
 Schweigert, Bryon F. A letter about Letters (letter), 1651  
 Scott, Evelyn Gray Appreciation expressed for Francke tribute (letter), 1660  
 Scott, Evelyn Gray Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 466  
 Segal, Harold J. Book review, 1421  
 Segall, L. Elliott Comparison of two methods of observing work areas in a hospital pharmacy, 59  
 Seifert, Randall D. see Rector, Tom S., 1561  
 Sesin, G. Paul see Kirschenbaum, Harold L., 1464  
 Sesin, G. Paul see also Sesin, George P. (same person)

Sesin, George P. Folic acid hypersensitivity and fever: A case report, 1565  
 Sesin, George P. see also Sesin, G. Paul (same person)  
 Sewell, Winifred Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 481  
 Shaw, Stanley M. see McBride, Martin H. D., 1370  
 Shearer, Cameron A. see Parker, William A., 505, 1103  
 Shelver, William H. see Arnold, Lawrence A., 1059  
 Sherrin, Thomas P. see Allinson, Russel R., 513, 1035  
 Shulman, Jonas A. see McGowan, John E. Jr., 376  
 Silberg, Ronald see Anderson, C. W. David, 597  
 Simonsmeier, Larry M. Pharmacy inspections: Constitutional without a warrant?, 85  
 Simonson, William Estimated versus measured serum digoxin levels (letter), 166  
 Simonson, William see also Stennett, Douglas J., 657  
 Simpson, Thomas R. see Schweigert, Bryon F., 1651  
 Silverman, Harold M. ASHP membership dues (letter), 1307  
 Skolaut, Milton W. Report of Treasurer, 946  
 Skolaut, Milton W. see also Ziser, Mark, 1090  
 Skoutakis, Vasilios A. see Czajka, Peter A., 1087  
 Slatery, John T. Pharmacokinetic model of acetaminophen elimination (letter), 440  
 Slotfeldt, Marilyn L. Determining chronic oral dosage regimens for theophylline (letter), 745  
 Slotfeldt, Marilyn L. Dose-dependent versus first-order kinetics in theophylline elimination (letter), 453  
 Slotfeldt, Marilyn L. Reliability of theophylline clearance in determining chronic oral dosage regimens, 66  
 Smith, Dorothy L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 479  
 Smith, Gary H. Book review, 1417  
 Smith, Joe E. see Anderson, Joan M., 791  
 Smith, Kristie A. see Mutchie, Kelly D., 785  
 Smith, William E. Charging for hospital pharmaceutical services: Product cost, per diem fees and fees for special clinical services, 355  
 Smith, William E. Jr. see Hlynka, John N., 1347  
 Sonnedecker, Glenn Remarks at the memorial service (tribute to Donald E. Francke), 459  
 Sorkness, Ronald Therapeutic problem solving: A systematic approach, 798  
 Souney, Paul F. see Feldman, Marvin J., 1545  
 Sparkman, Helen E. Experience with cimetidine oral suspension formulation (letter), 600  
 Speedie, Marilyn K. see Knapp, Deanne E., 1334  
 Spigiel, Robert W. Comprehensive pharmaceutical services in the emergency room, 52  
 Spivey, R. J. In vitro acid reactivity of three commercial antacid tablets, 660  
 Spurbeck, George H. see Arnold, Lawrence A., 1059  
 Stach, Paul E. Book review, 1253  
 Stach, Paul E. see also Allinson, Russel R., 513, 1035  
 Stallings, Sylvia B. Comparison of natriuretic and diuretic effects of single and divided doses of furosemide, 68  
 Stanaszek, Walter F. see Mitchell, Gary W., 653  
 Stein, Z. L. G. Diagnosis of sarcoidosis (letter), 744  
 Stein, Z. L. G. Pokeweed-induced gastroenteritis (letter), 1303  
 Stein, Z. L. G. Quinidine-digoxin interaction (letter), 1307  
 Steiner, Gilbert A. Book reviews, 386, 702  
 Steinke, William E. see Reinders, Thomas P., 645  
 Stennett, Douglas J. Effect of membrane filtration on 10-mg/ml cefazolin admixtures, 657  
 Stennett, Douglas J. see also Simonson, William, 166  
 Stewart, Kenneth R. see Gupta, V. Das, 1094  
 Stewart, Ronald B. Book review, 1421  
 Stewart, Ronald B. Dermatologic adverse drug reactions in hospitalized patients, 609  
 Stewart, Ronald B. see also Murphy, John E., 641  
 Stewart, Ronald B. see also Yost, Richard L., 1372  
 Stiles, M. Lou see Frech, Gary, 1672  
 Stitt, Richard P. see Waller, Elaine S., 1193  
 Stolar, Michael H. Assuring the quality of intravenous admixture programs, 605  
 Stolar, Michael H. Editorials, 170, 1053  
 Stolar, Michael H. Hospital pharmacy purchases and inventories, 650  
 Stolar, Michael H. National survey of hospital pharmaceutical services—1978, 316  
 Stolley, Stephen N. see Greenlaw, Cai W., 920  
 Sturgeon, Roy see Athanikar, Narayan, 511  
 Sula, Joseph A. Structured educational program for staff development, 50  
 Summerfield, Marc Warning label for intravenous use of vesicants (letter), 1470  
 Summerfield, Marc R. Book review, 828  
 Superstine, Edward Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 476  
 Swanson, Larry N. Book review, 1579  
 Swartz, Allan J. Staff evaluation, 187  
 Swerling, Richard Importance of maintaining and



promoting prescription compounding skills (letter), 1477

## T

- Tallett, Eric R. Assuring the quality of intravenous admixture programs (letter), 1317  
 Talley, C. Richard News, 410, 1128  
 Tanaka, Gerald J. Pharmacist-prepared drug therapy reviews for family practice medical residents (letter), 1044  
 Tatro, David S. Book review, 391  
 Tatro, David S. Computer-based system for adverse drug reaction detection and prevention, 198  
 Teasley, Kathy M. see Hak, Lawrence J., 1036  
 Tempio, Joseph S. Extemporaneous preparation of cimetidine oral suspension (letter), 1039  
 Tharaldson, Thomas see Krier, Thomas, 305  
 Thomas, Russel R. Counter-detailing of drugs by pharmacists (letter), 888  
 Tobin, Morris see Haughey, David B., 1377  
 Tomasulo, William J. see Levine, Howard G., 788  
 Tortorici, Michael P. Formulation of a cimetidine oral suspension (letter), 22  
 Traub, Scott I. Definition of clinical pharmacy (letter), 296  
 Treadwell, Barbara E. Thiopental sodium and pentobarbital sodium in the treatment of Reye's syndrome (letter), 1490  
 Trestrail, John H. III Book reviews, 823, 1417  
 Tribble, Dennis A. Unit-of-use versus traditional intravenous piggyback drug administration systems (letter), 739  
 Troutman, William G. see Weber, Stanley S., 1567  
 Truque, Laurence see Weber, Stanley S., 1567  
 Tuttle, C. Brian Book review, 1721

## U

- Uliana, Mark Allergy labels for unit dose medication drawers (letter), 1024  
 U.S. General Accounting Office GAO report on hospital purchasing and inventory management, 1171

## V

- Valette, Guillaume Appreciation expressed for Francke tribute (letter), 1660  
 Vander Salm, Thomas J. see Welch, Gary W., 446  
 Van Leuven, Marcel see Athanikar, Narayan, 511  
 Varano, Carmine The Donald E. Francke tribute (letter), 743  
 Visconti, James A. see Rucker, T. Donald, 1099  
 Vitale, Paul J. see Summerfield, Marc, 1470  
 Vlases, Peter H. Urine test as a potential aid in testing for patient compliance with methyldopa therapy (letter), 1046

## W

- Wagner, Frederick H. see Roffe, Bruce D., 211  
 Wagner, James R. see Hanson, Don B., 1197  
 Walker, H. Kenneth see McGowan, John E. Jr., 376  
 Wallace, David L. see Plein, Joy B., 44  
 Waller, Elaine S. Relapsing polychondritis in a Latin American man, 806  
 Wallner, Jon N. Survey of outpatient pharmaceutical services in university hospitals, 1193  
 Wasserman, Albert J. see McKenney, James M., 1691  
 Watanabe, Arthur S. see Conner, Christopher S., 906  
 Watson, Bill Absence status and the concurrent administration of clonazepam and valproate sodium (letter), 887  
 Weber, Robert E. Readability of PPIs (letter), 305  
 Weber, Stanley S. Effect of hemodialysis on plasma naproxen concentration, 1567  
 Weg, John G. see Slotfeldt, Marilyn L., 66  
 Weiblen, Jack W. see Smith, William E., 355  
 Weinberger, Miles Dose-dependent versus first-order kinetics in theophylline elimination (letter), 452  
 Weiner, Bruce Salt substitute as a potassium supplement (letter), 444  
 Welch, Gary W. Hemolysis caused by mislabeled saline solution (letter), 446  
 Welco, Alan see Athanikar, Narayan, 511  
 Welsh, W. J. see McLean, J. R., 1039  
 Wertheimer, Albert I. Book review, 1588  
 Wertheimer, Albert I. see also Bootman, J. Lyle, 368  
 Whalen, Forrest J. Availability of insulin from continuous low-dose insulin infusions, 330  
 White, Eugene V. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 480

- Whiten, Ron E. Comparison of magnesium-aluminum liquid antacids (letter), 1316  
 Whiten, Ron E. Formulary selection of magnesium and aluminum combination liquid antacids (letter), 739  
 Whittet, T. Douglas The transition from apothecary to pharmacist in British hospitals, 492  
 Wiernik, Peter H. see Bender, John F., 1063  
 Williams, Frank F. see Thomas, Russel R., 888  
 Williams, Paul J. see Hak, Lawrence J., 1036  
 Wilson, Andrew L. see Schumacher, Gerald E., 802  
 Wilson, Emery see Magera, Barbara E., 1062  
 Winters, J. H. M. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 482  
 Wissinger, Robert A. see Gouveia, William A., 887  
 Wolfe, Lawrence W. see Thomas, Russel R., 888  
 Wood, George C. see Czajka, Peter A., 1087  
 Wood, Warren A. TPN formulations (letter), 29  
 Woodcock, Thomas M. see Hoffman, Dennis M., 1536  
 Worthen, Leonard R. see Mattea, Edward J., 1156  
 Wyatt, Benji K. Charging for hospital pharmaceutical services: Flat fee based on the medication record, 365

## Y

- Yaeger, Donna M. see Knapp, Deanne E., 1334  
 Yost, Richard L. ASHP Midyear Clinical Meeting papers: 1967-1978, 1372  
 Young, W. Wayne see Darr, Marilyn S., 63

## Z

- Zalai, K. Appreciation expressed for Francke tribute (letter), 1660  
 Zaske, Darwin E. see Bootman, J. Lyle, 368  
 Zaske, Darwin E. see also Kellenberger, Thomas A., 230  
 Zellmer, William A. Editorials, 31, 169, 307, 603, 747, 891, 1169, 1319, 1490, 1663  
 Ziser, Mark Regulating intravenous fluid flow: Controller versus clamps, 1590

## Advertising Index

## A

- Abbott Laboratories  
 H-BIG, 291, 547  
 IVEN-2, 102-103, 239, 392-393, 426, 672-673, 720  
 Panheprin, 873-874, 1029-1030, 1273-1274, 1433-1434, 1723-1724  
 Adria Laboratories, Inc.  
 Adrucil, 16-17, 262-263, 382-383, 530-531, 586-587, 858-859, 1244-1245, 1296-1297  
 AFS International/Intercultural Programs  
 Institutional, 824  
 American Lung Association  
 Christmas Seals, 1732  
 American Pharmaceutical Association  
 APhA Drug Names, 815  
 American Pharmacy Corporation  
 Positions Available, 94, 234, 286  
 American Society for Parenteral and Enteral Nutrition, Inc.  
 4th Clinical Congress, 1416  
 American Society of Hospital Pharmacists  
 American Hospital Formulary Service, 1022, 1226  
 Handbook of Drug Therapy, 1251  
 Handbook of Institutional Pharmacy Practice, 1257  
 Handbook on Injectable Drugs, 568, 1664  
 International Pharmaceutical Abstracts, 434  
 Manual for Hospital Pharmacy Technicians, 1150  
 Medication Teaching Manual, 928  
 Patient Education Programs, 860  
 Sourcebook on Computers in Pharmacy, 927  
 Sourcebook on Unit Dose Drug Distribution Systems, 1110, 1146  
 Wiley's Professional Development Programs, 432  
 Ames Color-File, Division of Ames Safety Envelope Company  
 Kompres Mobile Shelving, 1281  
 Arnar-Stone Laboratories, Division of American Hospital Supply Corporation  
 Breytlyol and Intropin, 532-536, 688-692, 828-832  
 Intropin, 244-246, 282-284, 882-883, 1270-1271  
 Position Available, 1613

- Ascot Hospital Pharmaceuticals, Inc.,  
 Hydroxyzine, 1587  
 Automated Prescription Systems, Inc.  
 Baker AutoScript, 1409

## B-C

- Becton-Dickinson, Division of Becton, Dickinson and Company  
 Glaspak Syringe, 99, 1455  
 Beecham Laboratories  
 Ticar, 730-732, 1130-1132, 1298-1300, 1628-1630  
 Breon Laboratories, Inc.  
 Bronkosol, 1460-1461, 1620-1621  
 Bristol Laboratories, Division of Bristol-Myers Company  
 Amikin, 23-26, 235-238, 273-276  
 Cefadyl, 156-158, 388-390, 428-430, 818-820, 884-886, 1032-1034, 1254-1256  
 Kantrex, 100-101, 164-165, 296-297, 584-585, 834-835, 986-987, 1235-1226, 1383-1384  
 Mexate, 1482-1484, 1637-1639  
 Stadol, 3-6, 265-268, 287-290, 435-438  
 Burrong Medical Products, Inc.  
 Filter Needle II, 967  
 Filtration Systems, 556-557, 700-701, 1436-1437  
 Secondary I.V. Set, 1320  
 Burroughs Wellcome Company  
 Empirin  $\bar{c}$  Codeine, 1582, Dec-IPC  
 Lanoxin, 125-126, 411-412, 679-680, 973-974, 1381-1382, 1655-1656  
 Canadian Pharmaceutical Association  
 Position Available, 966  
 Cedars of Lebanon Health Care Center  
 Positions Available, 678  
 Connaught Laboratories, Inc.  
 Albuconn and Tet-Conn-G, Jan-OBG, Feb-OBG, 380, 687, Aug-OBG, 1429

- Tubersol, 13, 253, 402, 441, May-OBG, 733, 868, 1023, 1283, 1423, Nov-OBG, 1622  
 Cook County Hospital  
 Position Available, 1129  
 Cooper Laboratories  
 Kay Ciel, 252, 569  
 Cutter Biological, Division of Cutter Laboratories, Inc.  
 Koite, 396-398, 588-590, 994-996, 1164-1166, 1428-1428, 1462-1464  
 Pediatric Plasma Fractions, 292-294, 538-540, 668-670  
 Plasbumin, 152-154, 442-444, 836-838, 1048-1050, 1260-1262, 1288-1290  
 Plasmanate, 871-872  
 Cutter Medical, Division of Cutter Laboratories, Inc.  
 Colorcheck System, 811-814, 929-932, 1017-1020, 1151-1154  
 Institutional, 1137-1139, 1313-1315, 1607-1609

## D-F

- Drug Intelligence Publications, Inc.  
 Handbook of Clinical Drug Data, 524  
 Problems in Pediatric Drug Therapy, 1729  
 Elkins-Sinn, Inc., Subsidiary of A. H. Robins Company  
 Hep-Lock, 104, 138, Mar-OBG, Apr-OBG, Lidocaine, 703, Jun-OBG, Jul-OBG, 1027, Sep-OBG, Oct-OBG, 1452, Dec-OBG  
 Elsevier North Holland Inc.  
 Drug Therapeutics, 805  
 Pharmacy International, 1578  
 Emblem-Medic Industries  
 Unit Dose Packaging, 117, 413, 857  
 Facts and Comparisons  
 Publication, 1115, 1246, 1414

## Index

**Flint Laboratories, Division of Travenol Laboratories, Inc.**  
Synthroid, 542-543, 708-709  
**E. Fougera & Co. Division of Byk-Gulden, Inc.**  
Efodine, 439, 1051, 1240  
Foilpac, 592  
Institutional, 1390  
Surgilube, 717  
**Fresno Community Hospital and Medical Center**  
Position Available, 1569

## G-I

**Geigy Pharmaceuticals, Division of Ciba-Geigy Corporation**  
Lopresor, Jan-IFC, Feb-IFC, Mar-IFC, Apr-IFC, May-IFC, Jun-IFC, Aug-IFC, Sep-IFC, Oct-IFC, Nov-IFC  
**Gem Refrigerator**  
Refrigerator, 88, 261, 396, 558, 600, 822, 979, 1123, 1258, 1405, 1554, 1657  
**Hamilton Industries**  
Laboratory Equipment, 559, 1157  
**HPI Hospital Pharmacies**  
Institutional, 1458  
Positions Available, 1726  
**Hoechst-Roussel Pharmaceuticals, Inc.**  
Lasix, 421, 671  
**IMED Corporation**  
Volumetric Infusion Pumps, 667, 1318  
**International Pharmaceutical Federation**  
Membership, 1733  
**Invenex Laboratories**  
Magnesium Sulfate Injection, 129-130  
Lidocaine, 159-160  
**IVAC Corporation**  
IVAC 230 Controller, 8-9, 134-135, 302-303, 988-989, 1142-1143, 1388-1389, 1486-1487  
IVAC 630 Pump, 551-554, 576-577, 734-735

## J-L

**Jewett Refrigerator Company, Inc.**  
Refrigerators, 1028, 1397, 1625  
**Johnson & Johnson**  
Pancrease, 136-137, 450-451, 740-741, 1008-1009  
**Kewaunee Scientific Equipment Corporation**  
Institutional, 1241, 1401, 1584  
**Knoll Pharmaceutical Company**  
Dilauid, 155, 449, 1047, 1479  
**Lansing General Hospital**  
Position Available, 1569  
**Lea & Febiger**  
Publications, 699  
**Lenox Hill Hospital**  
Position Available, 1569  
**Lifemark Corporation**  
Grant Awards Program, 1589  
Positions Available, 1731  
**Eli Lilly and Company**  
Institutional, 106-107, 142-143, 298-299, 544-545, 578-579, 840-841, 876-877, 1126-1127, 1140-1141, 1386-1387, 1456-1457, 1642-1643  
Kefzol, 447-448, 693-694, 727-728, 997-998, 1045-1046, 1149-1150, 1287, 1605

## M

**MacBick, Division of C. R. Bard, Inc.**  
Medication Carts, 1263, 1617  
**Market Forge**  
Medication Carts, Apr-IBC  
Medication Handling Equipment, 7, 1449, 1627  
**McGaw Laboratories, Division of American Hospital Supply Corporation**  
Accumed, 1040-1042, 1304-1306, 1574-1575, 1644-1646  
Institutional, 1471-1476, 1631-1636  
**Mead Johnson Pharmaceutical Division, Mead Johnson and Company**  
Mucomyst, 1596-1598, 1648-1650  
Unit Dose, 108, 240, 304  
**Medi-Dose, Inc.**  
Medi-dose/Medi-cup System, 19, 250, 453, 725, 1025, 1417

**Herman Miller, Inc.**  
The Co/Struc System, 133, 387, 445, 1003, 1167, 1595  
**Millipore Corporation**  
Addi-Chek, 10, 278, 580, 1052, 1259  
Millex, 1411, 1413, 1415, 1579, 1581, 1583  
**Modern IV Practices**  
MIVP Program, 1248-1249, 1418-1419  
**Modern Metals Industries, Inc.**  
Unit Dose Systems, 1028, 1407

## N-P

**National Society for the Prevention of Blindness**  
Institutional, 856  
**Ochsner Foundation Hospital**  
Position Available, 1727  
**The Ohio State University Hospitals**  
Pharmacy Technician Training Manual, 928  
**Omnimed, Inc.**  
Locks and Links, 597  
Perineze, 1589  
**Organon Pharmaceuticals, Division of Organon Inc.**  
Deca-Durabolin, 95, 171, 277, 562, 682  
Hexadrol, 121, 251, 417, 458, 713, 801, 1102, 1229, 1441, 1560  
**The Owen Company**  
Positions Available, 846, 1124, 1269, 1422, 1478, 1727  
**Parke, Davis and Company, Division of Warner-Lambert Company**  
Documed, 1054, 1170, 1492  
Nitrostat, 71, 109, 286, 391, 666, 686, 927, 975, 1247, 1278  
Uni/Use, 866-867, 1120-1121, 1238-1239, 1292-1293, 1610-1611  
**Pharmaceutical Associates**  
Generic Liquid Pharmaceuticals, 1491  
**Pharmaseal Laboratories, Division of American Hospital Supply Corporation**  
Pharm-Aide, 1110, 1430, 1481  
**Philadelphia College of Pharmacy and Science**  
Pharmacy Management, 12, 529  
**Philips Roxane Laboratories, Inc., a Boehringer Ingelheim, Ltd. Company**  
Liquid Unit Dose, 1004-1005, 1264-1265, 1424-1425, 1468-1469  
Lithium Citrate, 21, 257, 379, 433, 681  
Milk of Magnesia, 30, 168, 306, 454, 602, 746, 890  
**Production Equipment, Inc.**  
Counters, 151, 565, 743, 1113, 1392, 1659  
**PSG Publishing Company**  
Clinical Pharmacy Sourcebook, 1116  
**The Purdue Frederick Company**  
Betadine, 32, 385, 707, 889, 1275, 1439

## R-T

**Red Cross**  
CPR Training, 856  
**Reynolds and Reynolds**  
Unit Dose System, 1459, 1715  
**Roche Laboratories, Division of Hoffmann-La Roche Corporation**  
Institutional, 118-119, 254-255, 404-405, 526-528, 683-685, 825-827, 1279-1280, 1375-1376, 1571-1572  
**Roche Products, Inc.**  
Dalmane, 97-98, 399-400, 573-574, 1161-1162, 1601-1602, 1640-1641  
**Sandoz Pharmaceuticals**  
Institutional, 457, 1031, 1647  
Sando-Pak, 167, 839, 1385  
**Searle Laboratories, Division of Searle Pharmaceuticals, Inc.**  
Institutional, 285, 537, 575, 833  
**Sigmamotor, Inc.**  
Sigma 5000, 591, 999  
**Smith Kline & French Laboratories, Division of SmithKline Corporation**  
Ancef, 111, 259, 401, 523, 705, 851, 990-992, 1014-1016, 1158-1160  
Compazine, 144-145, 548-549, 718-719, 1006-1007, 1242-1243, 1294-1295, 1618-1619  
Institutional, 248-249, 422-423, 696-697, 842-843, 1466-1467  
Tagamet, 1450-1451, 1652-1653  
**Stony Brook University Hospital**  
Positions Available, 971  
**St. John's University**  
Positions Available, 170

**Stuart Pharmaceuticals, Division of ICI Americas, Inc.**  
Efferyllium, 127, 260, 407, 521, 695, 748,  
**SystaModules, Division of General Equipment Corporation**  
Institutional, 84, 172, 415, 567, 604, 816, 892, 1111, 1252, 1412, 1580, 1662  
**Teach'em, Inc.**  
Voices, 83, 855, 1720  
**Travenol Laboratories, Inc.**  
Filters, 879-880, 1037-1038, 1267-1268, 1301-1302, 1557-1558, 1717-1718  
Mini-Bag, 112, 865  
Travasol, 147-150, 981-984  
Viaflex, 269-270, Jun-IBC, Jul-IBC, Aug-IBC, 1168, Oct-IBC, 1488, Dec-IBC

## U

**UCLA**  
Positions Available, 710  
**United Hospital Supply Corporation**  
Unit Dose Medication Systems, 875, 1035  
**United States Pharmacopoeial Convention**  
Publication, 1585  
**The United Way**  
Institutional, 928  
**University of Alberta**  
Positions Available, 406  
**University of Arizona**  
Positions Available, 406, 678, 1625  
**University of Arkansas**  
Position Available, 560  
**University of Colorado**  
Positions Available, 229, 403, 416, 980, 1722  
**University of Iowa**  
Clinical Pharmacy Fellowship, 561  
**University of Michigan Hospitals**  
Positions Available, 1266, 1431, 1590  
**University of Minnesota**  
Position Available, 1722  
**University of Pennsylvania**  
Symposium, 566  
**University of Southern California**  
Position Available, 1380, 1554  
**University of Tennessee Center for the Health Sciences**  
Training Programs, 704  
**University of Texas System Cancer Center**  
Oncology Symposium, 1250  
**University of Wisconsin**  
Position Available, 1431  
**The Upjohn Company**  
Cleocin, 14-15, 394-395, 594-595  
Institutional, 848-849  
Motrin, 1309-1312, 1591-1594  
**Upsher Smith Laboratories, Inc.**  
Acetaminophen, Sep-IBC, Nov-IBC  
Klor Con "G", Jan-IBC, Feb-IBC, Mar-IBC, May-IBC  
**USV Laboratories, Division of USV Pharmaceutical Corporation**  
M.V.I., 598-599, 852-853, 1276-1277, 1442-1443, 1576-1577

## W-Y

**Warner/Chilcott, Division of Warner-Lambert Company**  
Dispon-a-Vial, 162-163, 424-425, 844-845  
**Waterloo Industries**  
Med-Cart, 384, 525, 861, 1021, 1253, 1421, 1603  
**Wayne State University**  
Position Available, 980  
**Wheaton Scientific**  
I.V. Additive Pump Chamber Assembly, 243, 1573  
Uni-Dose, 241, 817, 1117, 1719  
Unispense, 242, 823, 1148  
Zippettes, 105, 1721  
**Winthrop Laboratories**  
Carpject, 247, 301, 541, 601, 737, Jul-IBC, 1043, 1144  
**Wyeth Laboratories**  
Heparin, 81-82, 309-310, 711-712, 977-978, 1227-1228, 1555-1556  
**Yale-New Haven Hospital**  
Position Available, 1316, 1727

